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Abstract
Clostridium difficile is a frequent cause of healthcare-associated infections (HAI) and is
associated with increased risk of morbidity and mortality. Studies suggest environmental
and host characteristics increase patient’s susceptibility to C. difficile infection (CDI).
However, few studies have examined the risk of CDI among those with diabetes or
patients in the acute rehabilitation (AR) setting. A case-control study, using secondary
data (n = 473), evaluated the relationship between CDI and diabetes and identified
modifiable environmental exposures. An ecosocial framework was used to examine the
relationship between these two complex diseases among hospitalized patients in an AR
setting. Results of the multiple logistic regression showed that patients with diabetes
experienced 2.5 times the risk for CDI (p = 0.03) compared to non-diabetic patients.
Multiple logistic regression was also used to assess for modifiable exposures among AR
patients with diabetes only. Findings from this sub-analysis found the significant
exposures in this population were antibiotics (OR = 3.9; p = 0.01) and insulin use (OR =
2.6; p = 0.015), suggesting an effect on the intestinal microbiome. Understanding the
relationship between CDI and diabetes among the AR population promotes positive
social change through the reduction of CDI associated morbidity and mortality among
diabetic patients. Findings from this study support antibiotic stewardship efforts across
the spectrum of healthcare delivery and the development of new strategies to decrease the
economic burden associated with CDI for individuals, healthcare facilities, and at the
national level.
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Chapter 1: Introduction to the Study
Introduction
A key public health issue is healthcare-associated infections (HAI) and the
prevention of these infections as a measure of healthcare quality. This research study
proposes to investigate the relationship between diabetes and Clostridium difficile
infection (CDI) in a healthcare setting. C. difficile is a spore forming bacteria found in
the environment that affects a range of outcomes in those infected. Outcomes range from
mild or moderate diarrhea, to severe life-threatening inflammation of the colon, and death
(Cohen et al., 2010). Increasing prevalence of CDI in the United States in recent years
has resulted in a multiple level approach to prevention (The White House, 2015). This
study will evaluate the relationship between diabetes and CDI to support efforts to reduce
the incidence of CDI among hospitalized patients. People with diabetes are a population
group with frequent healthcare exposure across the continuum of healthcare delivery
(Booth & Hux, 2003). Understanding the relationship between different population
groups can promote positive social change by identifying and targeting infection
prevention measures in a population group with high healthcare utilization and exposure.
Prevention efforts, in turn can improve healthcare outcomes and reduce the costs of
healthcare delivery. Information gained from this research has the potential to inform
and support healthcare professionals and public health policy makers’ efforts to
implement clinically relevant and effective decisions related to CDI prevention.
This first chapter presents background information regarding the burden of
diabetes and CDI, describes the purpose of the study, the research questions and
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hypotheses this study will address. The theoretical framework, methodology, definitions,
assumptions, scope, limitations, and significance of the study are also described in this
chapter.
Background
C. difficile is a leading cause of healthcare-associated infections in the United
States, associated with increased morbidity and mortality among infected patients (Magill
et al., 2015; Lessa et al., 2015). The economic burden is also significant, with estimated
costs in the billions of dollars annually (Desai et al., 2016). The Centers for Disease
Control and Prevention (CDC) has identified CDI as an immediate public health threat
requiring urgent and aggressive prevention and control measures (Centers for Disease
Control and Prevention [CDC], 2013). Efforts to understand the burden of CDI in
healthcare settings has resulted in national surveillance and reporting of CDI incidence.
Exposure to antimicrobial agents has been strongly associated with the development of
CDI, in part due to alterations in host intestinal microbiota (Loo et al., 2011; Owens,
Donskey, Gaynes, Loo, & Muto, 2008). Other important factors associated with an
increased risk of CDI include age and underlying disease, for example, diabetes (Kyne,
Sougioultzis, McFarland, & Kelly, 2002; Wenisch et al., 2012).
Diabetes disease presents a significant health burden, affecting a sizable
proportion of the U. S. population (CDC, 2017). Evidence that those with diabetes could
be at increased risk for CDI is unclear and often conflicting (Qu & Jiang, 2014). In some
studies diabetes was associated with increased risk for CDI (Shakov, Salazar, Kaqunye,
Buddora, & DeBan, 2011; Wenisch et al., 2013; Zilberberg, Reske, Olsen, Yan, &
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Dubberke, 2014), while others report finding no significant association (Daneman et al.,
2014; Freedberg, Salmasian, Friedman, & Abrams, 2013; Henrich, Krakower, Bitton, &
Yokoe, 2009). Researchers have also reported lower a risk of severe CDI disease (Rao et
al., 2013) and CDI mortality among patients with diabetes (Stewart & Hollenbeak, 2011),
In addition, studies examining CDI risk factors have not specifically included diabetes as
a variable (Loo et al., 2011; Morrison et al., 2011).
The relationship between diabetes and CDI is plausible (Qu & Jiang, 2014). It
has been suggested that the presence of diabetes increases susceptibility to infectious
agents through alterations in immune function (Bertoni, Saydah & Brancati, 2001; Muller
et al., 2005; Shah & Hux, 2003). Such susceptibility to infections may lead to increased
exposure to antibiotics. Changes in the gut microbiota following exposure to
antimicrobials could explain the increased risk for CDI associated with recent antibiotic
use (Theriot et al., 2014), by providing an opportunity for C. difficile to germinate and
grow. There is also evidence demonstrating that C. difficile growth is aided by elevated
sialic acid levels (Ng et al., 2013). Sialic acid, a protein bound carbohydrate, is found in
higher concentrations among diabetics compared to non-diabetics (Varghese, Asha,
Celine, & Prasanna, 2015). Differences in the ratios of gut microbiota utilizing sialic
acid as an energy source exist between those with and without diabetes disease (Larsen et
al., 2010). Differences and alterations to the gut microbiota of diabetic patient’s due to
host-derived sialic acid levels (Jandhyala et al., 2015) and increased exposure to
antimicrobials would suggest an increased risk for CDI among diabetics not consistently
supported in the literature (Qu, & Jiang, 2014).
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Purpose of Study
The primary purpose of this quantitative case-control study is to assess the
association between diabetes and CDI while controlling for selected environmental and
host characteristics. The independent variable is a diagnosis of diabetes disease, and the
dependent variable, a laboratory confirmed test for C. difficile. A second aim of this
study is to identify modifiable environmental and host characteristics that increase the
risk of CDI among hospitalized diabetics. The independent variables of interest are
antibiotic use, gastric acid suppressants, and body mass index(BMI). The dependent
variable is CDI. Control variables include age, ethnicity/race, gender, admission
diagnosis, comorbidities, functional status, and diabetes disease severity.
Research Questions and Hypothesis
Research Question 1: Is there any relationship between diabetes and CDI among
hospitalized patients in the acute rehabilitation (AR) setting?
Ho1: There is no relationship between diabetes disease and CDI among patients in
the AR setting.
H11: There is a significant relationship between diabetes and CDI among patients
in the AR setting.
Research Question 2: Are modifiable environmental (antimicrobial and
medication exposures) and host characteristics (behaviors, BMI, diabetes management)
associated with CDI among hospitalized diabetics in AR settings?
Ho2: There is no relationship between selected modifiable variables and CDI
among diabetic patients in the AR setting.
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H12: There is a relationship between modifiable variables and CDI among
diabetic patients in the AR setting.
Theoretical Framework
An ecological theoretical model is used to frame and guide this research study.
The ecological perspective uses a system- based approach; examining patterns of health
within the context of dynamic interrelationships between the biological, physical, social,
cultural, and historical contexts existing at the local and global level, as well as individual
attitudes and behaviors (McLaren & Hawe, 2005; Satariano, 2006). Ecological theory is
grounded in the assumption that demographic and socioeconomic differences influence
susceptibility and resilience to health risks (Satariano, 2006). Krieger (2011) further
developed this theory in the field of epidemiology, considering the multiple pathways
affecting the distribution of health and disease in populations. The key construct of
Krieger’s ecosocial theory is embodiment. Embodiment describes the biological
integration of social and ecological context through socially patterned and exposureinduced pathogenic pathways. These pathways are mediated by physiology, behavior,
and gene expression that affect the development of health and disease states (Krieger,
2012). Krieger’s (2008) ecosocial theory provides a framework to examine relationships
and distribution of disease at the individual and population level (Figure 1).
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Figure 1. The ecological and ecosocial concepts used as the theoretical framework to
examine the association between diabetes and CDI (Krieger, 2008, p. 224). Reprinted
with permission1.

Both diabetes and CDI are diseases associated with multiple risk factors
contributing to disease onset. Ecological and ecosocial theory provides a framework to
examine the complex connections that frequently exist between disease and health.
Diabetes, a chronic disease, has multiple pathways contributing to disease onset and
complications of disease (Hill et al., 2013a). CDI is also complex, in terms of exposure
risks associated with health care utilization (Burke & Lamont, 2014). An ecological
perspective expands on the agent, host, and environment concepts associated with
infectious disease epidemiology by acknowledging the broader context in which
infectious diseases occur and transmit among susceptible hosts (Satariano, 2006; Smith et
al., 2005). The ecological perspective also expands the biomedical perspective of
infectious disease causation and treatment (Armstrong, 2000), often present in healthcare
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settings. Identifying effective prevention measures requires an understanding of the
multiple pathways contributing to disease. Satariano (2006) suggests the ecological
approach examines the context in which individual’s function and respond, and provides
the opportunity for public health intervention when considering health through an
integrated and multilevel lens. Hill, Nielsen, and Fox (2013) also suggest the use of an
ecosocial perspective to frame prevention efforts. Especially, as this perspective
considers the environmental factors, social determinants, and the influence of public
policy on individual and population health and related behaviors (Hill, Nielsen, & Fox,
2013).
Nature of the Study
This study is observational in nature, using a case-control design to examine the
association between diabetes (independent variable), and CDI (dependent variable)
among adult patients in the AR setting. A case-control design allows the investigation of
associations between exposure and outcome. In case-control designs, cases, those known
to have the outcome of interest (dependent variable), are compared to a similar group in
which the outcome is absent (Szklo & Nieto, 2014). Comparison data regarding
exposure histories (independent variables) between the groups are analyzed to identify
factors associated with an increased risk of developing the disease or outcome of interest
(Szklo & Nieto, 2014). The decision to use a case-control design lies in its suitability to
investigate rare or infrequent outcomes, less than 20% (Aschengrau & Seage, 2008).
Previously published CDI estimates in the AR, indicate a prevalence of 15% (Mylotte,
Graham, Kahler, & Goodnough, 2000). Cases, defined as AR patients with a diagnosis
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of CDI, and controls, AR patients without a diagnosis of CDI, were drawn from the same
hospital population during the defined study period. Covariates of interest include sex,
race/ethnicity, BMI, and admission diagnosis. Other covariates include exposure to
medications (antibiotics, gastric acid suppressants, insulin, and oral antihyperglycemics)
environmental exposures (feeding tubes, prior locations), and comorbidity indices which
include cardiovascular disease, chronic kidney disease, hypertension, liver disease, and
dementia.
AR facility administrative data using International Classification of Diseases – 9th
Revision (ICD-9) diagnostic codes was used to identify cases and controls. Information
on independent variables for study participants was extracted from the AR facilities
medical records. Analysis methods included descriptive statistics and logistic regression
modeling.
Definitions
Acute Rehabilitation (AR) Hospital: A specialized inpatient setting for improving
a person’s health, function, mobility and independence following injury or illness, so they
may successfully return to home, work, and community activities (American Medical
Rehabilitation Providers Association [AAPM&R], 2016). Admission to acute medical
rehabilitation is based on the functional and/or cognitive deficits of the patient, the need
for medical supervision, the patient’s ability to participate in therapies, and realistic
outcome goals (American Academy of Physical Medicine & Rehabilitation, 2012).
Participation requirements include the ability to participate in at least three hours of
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therapy a day or 15 hours per week (Centers for Medicare & Medicaid Services [CMS],
2012.).
Binary Toxin: A toxin consisting of two separate components. Select strains of C.
difficile bacteria can produce binary toxins composed of an enzymatic activator and a
receptor-mediated binding component (Barth, Aktories, Popoff, & Stiles, 2004; Gerding,
Johnson, Rupnik, & Aktories, 2014).
Chronic Kidney Disease (CKD): describes the loss of kidney function, which may
result in end-stage renal disease requiring dialysis therapy. The assessment of the
presence of chronic kidney disease in study participants was based on documentation in
the medical record at time of admission.
Clostridium difficile: A spore-forming, gram-positive anaerobic bacillus that
produces two exotoxins, toxin A and toxin B, causing symptomatic infection (Carrico,
2013; Goudarzi, Seyedjavadi, Goudarzi, Aghdam, & Nazeri, 2014).
Clostridium difficile infection (CDI): A disease caused by the toxins produced by
the organism Clostridium difficile (Carrico, 2013).
Comorbidity: The presence of additional diseases in relation to an index disease in
a single individual. The term is used to measure the overall impact of multiple diseases
in an individual (Valderas, Starfield, Sibbald, Salisbury & Roland, 2009, p. 3.59).
Exotoxin: A “protein produced by a bacterium and released into its environment
causing damage to the host by destroying other cells or disrupting cellular metabolism”
(Carrico et al., 2013).
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Healthcare associated infection (HAI): Infections that occur while patients are
receiving treatment for medical or surgical conditions.
Microbiota: “ecological community of commensal, symbiotic, and pathogenic
microorganisms that literally share our body space” (Lederberg & McCray, 2001, para.
8). Intestinal microbiota describes the resident microorganisms in the intestine.
Proton pump inhibitors (PPI): A class of medications which inhibit gastric acid
secretion by the inhibition of the H+/K+ ATPase, in the parietal cells of the stomach. PPI
are used for the treatment of gastric and duodenal ulcers, gastroesophageal reflux disease,
and other excessive gastrointestinal acid secretory disorders (Drugs.com).
Social determinates of health: “the circumstances, in which people are born, grow
up, live, work and age, and the systems put in place to deal with illness. These
circumstances are in turn shaped by a wider set of forces: economics, social policies, and
politics” (World Health Organization, 2008).
Assumptions
The nature of this study assumes both cases and controls are from a dynamic
population, and that the control group is representative of the base population that
produced the cases (Aschengrau & Seage, 2008). Therefore, it is assumed that should a
member of the control group develop CDI, they would meet the case criteria. The
selection of cases and controls impacts the internal validity of the data (Szklo & Nieto,
2014). The assumption that both cases and controls are representative of the population
from which the sample is drawn relates to the external validity of the results (Creswell,
2009; Szklo & Nieto, 2014). In this study, cases and control subjects are drawn from a
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post-acute inpatient population. Admission to post-acute inpatient medical rehabilitation
is based on functional deficits, medical needs, and ability to participate in therapies
(AAPM&R, 2012; CMS, 2016). It is assumed that patients admitted to this setting meet
the criteria for inpatient rehabilitation as defined by the Centers for Medicare and
Medicaid (CMS, 2016). It is also assumed that documentation of diabetes and other
health and demographic related information represents accurate reporting of information
by the patient and healthcare providers. Another assumption of this study is that
laboratory tests positive for C. difficile toxin reflect an infective process, leading to the
clinical decision to test for a causative agent based on clinical guidelines (Cohen et al.,
2010). A final assumption is that susceptibility to disease encompasses the historical,
cultural, environmental, and socioeconomic factors and exposures across the life course
of individuals.
Scope and Delimitations
The scope of this study includes adult patients, over 18 years of age, admitted to
an acute medical rehabilitation hospital in New Mexico between January 1, 2009, and
September 30, 2015. Case finding used ICD-9 discharge diagnosis code 008.45 and a
positive laboratory confirmed test for C. difficile toxin. Positive test results included the
detection of toxins A or B, detection of C. difficile cytotoxin by PCR, or positive culture
for C. difficile. Controls included patients over 18 years of age admitted to the same
facility without a diagnosis of CDI during their hospitalization. Diabetic patients were
persons with a preexisting diagnosis of diabetes at the time of admission. Due to the
inability to accurately differentiate between T1D and T2D, all diabetic patients were
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included. Exclusions included patients 18 years of age or younger, and those admitted to
the facility with a diagnosis of CDI and receiving treatment on admission.
Limitations
Design and methodology limitations include the observational nature of the study,
which allows conclusions of association between variables but prevents establishing
cause and effect. Use of medical records to collect information on variables equates a
secondary data source. Secondary data sources are a recognized limitation as data was
originally collected as part of the routine care of patients and not the purposes of this
study. This limitation can affect the quality of the data due to missing or incomplete data,
inconsistencies in documentation between healthcare professionals, errors in
transcription, and misclassification of information during abstraction and coding. In
addition, self-reported information regarding race and ethnicity, and behaviors' such as
smoking are subject to recall bias. Measures to address this limitation include the
exclusion of cases with missing variables from the analysis. Selection bias is a concern
in case-control designed studies when differences exist in the selection of cases and
controls. This bias can occur when cases and controls are selected using different source
populations and different selection criteria. The use of a convenience, non-probability
sampling method also increases the potential for selection bias. Measures to overcome
this limitation include selecting both cases and controls from the same hospital
population, during the same time-period. Due to the infrequency of cases randomized
sampling techniques were not utilized.
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Generalizability to all healthcare facilities is another limitation. The study
population is limited to those admitted to an inpatient rehabilitation setting and findings
may not transfer to other healthcare or community settings. Population differences
resulting from a single state in the Southwest region of the United States may also limit
generalization of findings to other geographical regions.
Significance
This study, assessing the association between diabetes and risk for CDI has the
potential to effect positive social change in several ways. The effects of positive social
change could be measured through the reduction of CDI associated morbidity and
mortality among diabetic patients, and through reductions in the economic burden
associated with this infection. Results of this research could also contribute to the current
body of knowledge regarding risk factors associated with CDI in hospitalized patients by
identifying modifiable risk factors in this population. Determining the effect of
environmental and patient level characteristics is important to prevent the onset of
primary or recurrent infection. In addition, investigating the relationship between
diabetes and CDI within an ecosocial context could advance the theory that diabetics
develop unique intestinal microbiota and disruptions to this microbiota that contribute to
an increased risk for CDI.
CDI can negatively affect quality of life related to physical and social
functioning, and fear of recurrent disease (Guillemin et al., 2014; Weaver et al., 2017).
Patients with CDI may require readmission to the acute care setting. Readmission to
acute care not only affects the patient’s rehabilitation progress but also can have financial
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consequences for AR facilities (Ottenbacher et al., 2015). Identifying modifiable risk
factors among diabetic patients has implications for patient education and patient
participation in activities to reduce their risk for CDI. Clinical implications from this
research include identification and mitigation of risk among AR patients related to
differences in disease characteristics, and decisions regarding CDI prevention and
treatment options. Identification of risk factors in the AR population also has the
potential to support future research including clinical trials for medical interventions such
as fecal transplants, as well as antibiotic and vaccine research.
Summary
CDI presents a significant risk to hospitalized patients and the public’s health as a
leading cause of HAI. The emergence more virulent and resistant bacterial strains of C.
difficile highlights the need for concern among healthcare providers and consumers
(Carrico, 2013). Studies examining the prevalence of CDI in the United States have
focused on acute care settings (Magill et al., 2014) and risk factors associated with such
settings, limiting assessment of disease risks in post-acute settings (DePestel & Aronoff,
2013). In addition to the burden of CDI, the prevalence of diabetes in U.S. is estimated at
14% of the population (Menke, Casagrande, Geiss, & Cowie, 2015), with more than one
million new cases diagnosed each year (CDC, 2015, 2017). Patients with diabetes
experience high exposure to healthcare and subsequent risk for HAI (ADA, 2014).
Diabetes has been identified as a potential risk factor in the development and
severity of CDI (Wenisch et al., 2012). However, associations between the two variables
are not clearly established in the literature, and few studies have specifically investigated
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diabetes and risk for CDI (Eliakim-Raz et al.,2015). Assessing the relationship between
diabetes and CDI plays an important role in limiting morbidity and mortality in the
diabetic population, and identifying variables that could reduce exposure and subsequent
development of CDI
Chapter 2 will present a review of the published literature related to the
independent and dependent variables, providing support for the inconclusive findings
regarding an association between diabetes and CDI. Chapter 2 will critically review
studies to support the research problem, the research questions, and the significance of
the study. This review of the literature will also present research establishing the
theoretical framework used to identify selected variables and guide the analysis and the
interpretation of the study results.
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Chapter 2: Literature Review
Introduction
The purpose of this study is to evaluate the association between diabetes and the
risk of Clostridium difficile infection (CDI) among hospitalized patients in post-acute
settings and to identify modifiable environmental and host characteristics. Diabetes is a
chronic metabolic condition affecting more than 12% of the U. S. population (CDC,
2015, 2017). Persons with diabetes experience increased morbidity and mortality from
disease-related complications (ADA 2014, CDC, 2017), resulting in a greater need for
healthcare services. Frequent exposure to healthcare services and the healthcare
environment may place patients at increased risk for HAI (ADA, 2014). The elevated
risk for HAI is also supported by Gan (2013) who suggests host characteristics associated
with diabetes can increase susceptibility to infection.
Clostridium difficile has become a leading cause of HAI in the United States
(Magill et al., 2014). CDI is also associated with increased morbidity and mortality,
especially as resistant and increasingly virulent strains of C. difficile, such as genotype
027/BI/NAP1 emerge (He et al., 2013; Hensgens, Goorhuis, Dekkers, Van Benthem, &
Kuijper, 2013; Lessa et al., 2015). The increasing burden of CDI in healthcare settings
also has economic implications related to both in direct costs and indirect societal costs.
Total direct and indirect costs associated with healthcare-acquired CDI are estimated to
cost the U. S. 4.7 billion dollars annually (Desai et al., 2016). A marked increase over
previously reported estimates of almost 800 million dollars using 2008 data (McGlone et
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al., 2012). Review of the literature regarding CDI suggests environmental, and host
characteristics increase susceptibility to CDI across a variety of healthcare settings.
The purpose of this review is to present an overview of the literature significant to
this research topic. In addition, this literature review will show how the interplay
between environmental and host characteristics supports the plausibility of a relationship
between diabetes and CDI. An expansive body of literature exists across disciplines and
populations related to diabetes and C. difficile. However, research examining the
relationship between diabetes and CDI is limited, leaving a void in our understanding of
the risk and impact of CDI in diabetic patients in healthcare settings.
The first section of this chapter begins with a description of the methods and key
terms used to search the literature relevant to this research issue. This is followed by a
description of the theoretical foundation and the relevance in addressing this research
issue, a comprehensive review of the literature related to the key variables, and
conclusions based on the information presented.
Literature Search Strategy
A search of the literature was conducted to evaluate the current body of
knowledge regarding the relationship between diabetes and CDI. The following search
engines and databases, accessed through Walden University Library services were
utilized: EBSCOhost, CINAHL & Medline, ProQuest, and Science Direct. Internet
searches using the search engine Google Scholar were also conducted. The Walden
University Library location service requested difficult to obtain peer-reviewed articles.
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Bibliographies of published studies and review articles were also used to identify relevant
studies.
Key search words and terms were employed to identify pertinent articles related
to the research questions. Keywords were linked by Boolean search terms and included
the following:
•

Clostridium difficile, or C. difficile, or CDI, and diabetes, C. difficile and risk

factors, C. difficile and rehabilitation.
•

Diabetes and infection, and inflammation

•

Gut motility, gut microbiota

•

Ecosocial theory, ecosocial theory and diabetes, ecosocial theory and diabetes,

diabetes and health disparities
Scope of Literature Review
The scope of the literature review included an extensive search of published
materials in the past five years, extending into the past 20 years. Much research
examining risk factors for CDI occurred in the late eighties and early nineties. As
concerns regarding the prevalence of CDI have grown, there appears a resurgence of
research building on prior findings, particularly in genomic research. A variety of
literature was reviewed and includes various methodologies, ranging from experimental
in vitro studies, observational studies, meta-analysis, and reviews. Literature sources
included published peer-reviewed journal articles, published dissertations, and infectious
disease and disease prevention texts.
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Current Research Issues
A large body of current literature exists related to C. difficile and diabetes as
independent topics. A search of the ProQuest Dissertations and Theses database
identified several dissertations investigating CDI in both human and animal populations.
However, limited literature regarding C. difficile in diabetic or AR populations was
identified. The overall increase in publications over recent years, suggests unknown
factors contribute to CDI disease, including identification of high-risk groups, and
effective prevention measures across healthcare settings.
Theoretical Foundation
Ecosocial theory describes an epidemiology theory of disease distribution. Nancy
Krieger proposed this theory 1994 to address the limitations of traditional causal
relationships between specific agents and diseases to explain patterns and process of
disease (Krieger, 1994; Krieger, 2011). Ecosocial theory is one of several multilevel
social-ecological approaches identified in the literature, where health outcomes are
studied within the broader social and environmental systems in which people operate
(Susser & Susser, 1996). Krieger’s Ecosocial theory expands previous works in
epidemiological theory to include multiple system levels and tempo-spatial factors, such
as place of residence or community setting, and history to provide greater context when
describing factors contributing to health status and outcomes (Krieger, 2011).
Major Theoretical Propositions
Several core propositions underpin Ecosocial theory. These propositions have
application in understanding the relationship between diabetes and CDI. The premise of
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Krieger’s (2011) ecosocial theory is that peoples’ states of health, and disease, are shaped
by the literal embodiment of the lived experience in both social and ecologic contexts.
Thus, the way in which people live and interact within the world around them is
determined by current and changing societal arrangements of power, property,
production, and reproduction of social and biological life. Krieger defines embodiment
as the biological manifestation of cumulative exposures to the material and social world
in which we live, across the life course from utero to death (Krieger, 2005). Societal
arrangements and patterns influence the distribution of disease at various levels and along
different spatiotemporal scales in response to capacity and resources. For example,
multiple socioeconomic and environmental exposures during one’s life have been
identified as contributing to the biological embodiment of both diabetes and CDI (Eze et
al., 2014; Kivimäki et al., 2015; Stringhini, Zaninotto, Kumari, Kivimäki, & Batty, 2016).
Krieger (2011) also suggests that understanding the distribution of disease exclusively
from a disease process perspective fails to adequately explain why and how disease
patterns change over time and space (p. 215). Rather, ecosocial theory allows one to
consider how exposure, susceptibility, and resilience to social and biological phenomena
over time create causal pathways leading to a state of embodiment.
Analysis of the Literature
Ecosocial theory provides a framework to examine the social and ecological
factors contributing to health and health outcomes in epidemiologic and social research.
Previous works incorporating ecosocial theory include position papers examining the role
of ecosocial theory in public health research and public health policy (Bisung & Elliot,
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2014) and research studies across a broad range of health issues (Krieger et al., 2013;
Phillips et al., 2013; Shavers, Klein, & Fagan, 2012; Yamada & Palmer, 2007). Studies
using an ecosocial perspective address health outcomes across a variety of population
groups, with Krieger, frequently noted as the principal author. The variables most often
examined within the ecosocial framework are gender, race, ethnicity, and socioeconomic
disparities in health outcomes across a range of chronic and infectious diseases.
Ecosocial theory has also provided the theoretical framework in recently published
doctoral dissertations using qualitative and quantitative designs (Alford, 2014; Eke, 2013;
Marley, 2013). Although several social-ecological theories have been proposed in recent
years (Krieger, 2011; McLaren & Hawe, 2005), the increasing use of ecosocial theory in
dissertations (Alford, 2014; Eke, 2013; Marley, 2013) likely reflects increased
recognition of the complexities surrounding health behaviors' and outcomes. Despite the
potential of ecosocial theory to frame complex health issues, application of ecosocial
theory in understanding CDI is limited. The concepts of multiple pathways of exposure
that people experience across their life-course could influence their susceptibility or
resistance to this infection and may help identify disparities in disease distribution
Ecosocial Theory and Diabetes
Research into complex public health issues such as diabetes often uses an
ecological or multifaceted approach (Trickett & Bheeler, 2013). Krieger (2005) suggests
an ecosocial approach is well-suited to understanding the multiple factors contributing to
disease onset and related outcomes through the connection of biological and social
constructs. Despite the potential of ecosocial theory in diabetic research, researchers
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examining diabetes within this framework is limited, with dissertation research
predominating. Marley (2013) conducted a qualitative study examining the association
between the place where people live and the associated cultural, political, and social
context, and diabetes among White Mountain Apache. In this study, diabetes represented
the biological expression of embodiment, through cumulative exposure to environmental,
social, political, historical, and natural factors. Crocker (2013) also used ecosocial theory
to frame a quantitative analysis describing the health characteristics and social
determinants of Aboriginal peoples living outside tribal reservation with and without
diabetes in Canada.
Multiple causal pathways can lead to the onset of disease, and the ecosocial
concept of embodiment includes social, economic, environmental, political exposures.
The term social determinates of health describing the conditions in which people live,
learn, and work is one such pathway. Diabetes disease is strongly linked to social and
economic conditions (Clark & Utz, 2012). Hill et al. (2013) note factors contributing to
diabetes incidence and effective diabetic management are multi-level and impacted by
social, environmental, political, and historical context. They also discuss the
responsibility of public health agencies in reducing health disparities through data
collection and research. These research responsibilities align with the ecosocial concept
of agency, which refers to the need to monitor, address and explain disparities in health
outcomes. Krieger (2011) describes the concept of agency as a responsibility of
epidemiologic researchers. Although Hill et al. (2013) did not explicitly discuss
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ecosocial theory or the concept of embodiment, their article did detail the conceptual
pathways that can lead to disease.
Other multilevel theories incorporating social and ecological aspects similar to
ecosocial theory occur in diabetic population research. Chang and colleagues (2013)
examined characteristics associated with diabetes in a Hispanic population living in a
U.S. border town, using a socio-ecological framework. Findings from their multivariate
analysis showed dietary and biological factors most strongly associated with diabetes.
The authors used a multilevel socio-ecological framework which incorporated the
complexity and interrelatedness that exists between individual, relationship, community,
and societal factors. There are similarities between socio-ecological models and the
ecosocial theory proposed by Krieger. Both theories examine the interrelationships
between exposure and societal and ecosystem levels, but ecosocial theory also considers
how different temporal and spatial scales influence current and changing patterns of
health inequalities (Krieger, 2011, p.223).
Rationale for Theory Selection
Ecosocial theory provides a dynamic and multilevel theoretical framework for
research evaluating the association between diabetes and CDI in an AR setting. This
framework offers a way to explain how the accumulation and interaction of different
environmental conditions and experiences of hospitalized patients across the continuum
of care may impact susceptibility or resilience to disease (Krieger, 2001; Schneiderman,
Ironson, & Siegel, 2005). The concept of embodiment and the multifactorial pathways of
disease causation are applicable to understanding the complexities associated with CDI

24
and diabetes. For example, ecosocial theory provides a bridge connecting the physical
and social environments in which people live and interact and the complex ecological
structure of the intestinal microbiome. The intestinal microbiota forms unique
ecosystems which develop in response to various environmental and biological exposures
over an individual’s life-course (Rajilić-Stojanović, 2013). Krieger’s ecosocial theory
focuses on factors contributing to the distribution of disease not only from a life-course
perspective but also via multilevel processes and ecosystems. Such multilevel processes
and ecosystems can range from the individual micro level to global scale considerations
(Krieger, 2011). Using the ecosocial theory of distribution to view the issue of CDI
among the diabetic population supports examining the issue at the individual,
organizational, and population level. It also acknowledges host and environmental
factors that may contribute to an increased susceptibility or resilience based on previous
exposures and life course events. In addition, consideration of the ecosocial pathways
leading to CDI disease could identify opportunities for disease prevention
Literature Review Related to Key Variables and Concepts
Clostridium difficile Infection
C. difficile is a recognized pathogen in healthcare settings and a leading cause of
pseudomembranous colitis (Carrico, 2013). Today, C. difficile is a leading cause of HAI
(Magill et al., 2014). Lessa et al. (2015) reported an estimated 66% of CDI cases are
healthcare related compared to community acquisition. Similar estimates are also
reported by Olsen and colleagues (2016) across three national administrative databases.
The CDC considers C. difficile a high-level and urgent threat to public health. This basis
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for this assessment by the CDC comes from the organism’s natural resistance to multiple
antibiotics and the social and economic costs associated with this infection (CDC, 2013).
Researchers have consistently identified increased morbidity and mortality related
to CDI across a variety of patient populations. Bartlett and colleagues (1978) first
reported C. difficile as the causative agent in pseudomembranous colitis, refuting
previous assumptions that it was non-pathogenic (Bartlett, 2008). Experimental studies
investigating the action of C. difficile toxins suggest there are several mechanisms by
which both toxins damage and destroy cells, resulting in increased permeability and
inflammation of the intestine (Pruitt & Lacey, 2012), and systemic disease (Steele et al.,
2012). Complications from CDI can result in prolonged hospitalization, the need for
post-discharge care, and death. Tabak, Zilberberg, Johannes, Sun, and McDonald (2013)
estimated CDI attributable risk of death at 4.5%. However, a recent study by Desai et al.
(2016) using a broader population base estimated attributable mortality at 10%.
The ability of C. difficile to cause disease comes from the production of toxins
(Kelly & LaMont 1998; Kuehne et al., 2010). Primary exotoxins associated with CDI are
toxin A (TcdA) and toxin B (TcdB). A third binary toxin, C. difficile toxin (CDT), has
been identified in hyper-virulent C. difficile strains (Gerding et al., 2014). Advances in
molecular and genomic analyses are enabling researchers to identify the presence of
specific bacterial strains and toxins (Eckert et al., 2014; Janezic, Marín, Martín &
Rupink, 2015; Monot et al., 2015). Experimental studies investigating the action of
toxins in CDI indicate there are several mechanisms by which both toxins damage and
destroy cells, resulting in increased permeability and inflammation of the intestine (Pruitt
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& Lacey, 2012) and systemic disease (Steele et al., 2012). The presence of toxins not
only has significance for causing disease but is an essential marker in diagnostic tests.
Risk factors strongly associated with the onset of CDI are based on disruptions to the
microbiota of the host and include environmental exposure to antibiotics and gastric acid
suppressants. Other environmental factors include exposure to hospital environments.
Host risk factors identified in the literature include age, gender, race and the presence of
commodities, including diabetes disease.
Diabetes
Diabetes mellitus (DM), describes a chronic condition which results from the
inadequate production, or the inability to effectively utilize the hormone insulin, causing
blood glucose levels to increase (International Federation of Diabetes [IFD], 2014).
There are two main types of diabetes. The determination as to the type of diabetes
diagnosed depends on when the presentation of disease occurs and the cause of disease
onset. Type 1 diabetes (TD1) typically presents with acute metabolic imbalance
associated with autoimmune response and non-insulin production in children and young
adults (Forouhi & Wareham, 2014). Type 2 diabetes (T2D), the more prevalent of the
two categories, occurs because of alternations in insulin secretion, and or insulin
resistance. T2D is associated with increasing age, obesity, family history of diabetes,
gestational diabetes, physical inactivity, and race/ethnicity (ADA, 2014; CDC, 2015).
Dietary risk factors also exist for T2D and which include diets high in red or processed
meats, sugar-sweetened beverages, and limited intake of fruits and vegetables (Forouhi &
Wareham, 2014).
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Diabetes affects an estimated 23 million adults in the U. S, with T2D accounting
for 95% of all cases (CDC, 2017). Disparities in diabetes outcomes occur across a
variety of population groups, locations, and socioeconomic status. Fraze, Jiang, &
Burgess, (2010) found diabetes associated with frequent hospitalizations either as a direct
cause or from related complications, especially among those of low income. Education,
income, and neighborhood environment are consistent predictors of diabetes disease
(Garcia et al., 2015; Krishnan, Cozier, Rosenberg, & Palmer, 2010; Lee et al., 2011)
especially with cumulative exposure (Stringhini et al., 2016). Exposure to risk factors
can have a direct and indirect influence on physiological stress and inflammatory
responses within the body and are thought to explain the differences in disease risk within
populations (Garcia et al., 2010).
Untreated diabetes of any type can result in complications that lead to debilitating
systemic damage (Fowler, 2011). Complications affecting the gastrointestinal system
include gastroesophageal reflux, gastroparesis, and diabetes-related neuropathy which
increase susceptibility to enteric disease (Krishnan, Babu, Walker, Walker, & Pappachan,
2013). Mechanisms contributing to an increased risk of infection among those with
diabetes, include the impact of hyperglycemia and oxidative stress on immune system
function, the required immune response, and the unique attributes of the infective
organism including tissue tropism (Gan, 2013). For example, both Gan (2013) and Peleg,
Weerarathna, McCarthy, and Davis, (2007) suggested that defects in innate and adaptive
immunity resulting from impaired neutrophil and T-cell functions increase susceptibility
to infection among diabetic patients. Growing evidence also suggests a critical
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relationship between immune regulation and the intestinal microbiome (Gilbert et al.,
2016; Molloy, Bouladoux & Belkaid, 2012).
Intestinal Microbiota
The intestinal microbiota represents a diverse and dynamic ecosystem performing
essential mechanical and biochemical functions (Gilbert et al., 2016). Changes or
disruptions to the composition of this ecosystem can create dysbiosis and subsequent
illness (Gilbert et al., 2016; Rajilić-Stojanović, 2013). Within the bacterial ecosystem of
the intestine, select phyla have been identified as having specific metabolic functions
(Patterson et al., 2014). These functions include the breakdown and metabolism of
indigestible foods, the synthesis of vitamins, and the production of metabolites that
promote states of health and disease (Patterson et al., 2014; Rajilić-Stojanović, 2013).
For example, Clostridia species have an essential role in the fermentative digestion
process and are part of the normal intestinal flora. However, they also can cause disease
through the production of toxins. C. difficile, although a member of the Clostridia
species, is not commonly found within the normal intestinal flora of humans, due to the
bacteria’s inability to successfully compete for nutrients in the healthy microbial
ecosystem of the gut (Voth & Ballard, 2005). However, disruptions to the microbiota can
provide an opportunity for organisms such as C. difficile to establish a viable niche
(Theriot et al., 2013). The diversity of organisms is an indicator of a healthy microbial
ecosystem within the gut (D’Argenio, & Salvatore, 2015). Differences in the distribution
and diversity of the intestinal microbiota are found to exist among different population
groups (Escobar, Klotz, Valdes, & Agudelo, 2014; Mueller et al., 2006; Rajilić-
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Stojanović, 2013). Differences in diet, health behaviors', genetic characteristics, and
disease states likely explain these variations within the intestinal ecosystem. Buonomo
and Petri (2016) suggest that hospitalized patients are at risk for disturbances to the
diversity and health of the microbiota due to changes in diet, exposure to medications and
medical interventions. Hospitalized patients may also have an increased risk of exposure
to C. difficile spores due to the prevalence of CDI in hospital settings.
Scientific and technological advances are providing researchers with a
greater understanding as to the composition and function of the intestinal
microbiota (Gilbert et al., 2016). This knowledge includes the role of microbiota
in the development and maintenance of the immune system. There is also
evidence suggesting that the diversity and distribution of the host microbiota
within the gut plays a role in the onset of non-infectious diseases including
diabetes (Biedermann & Rogler, 2015). Diabetes can negatively impact immune
function and inflammatory responses through several pathways including the
composition and selective activity of commensal bacteria within the
gastrointestinal system (Brestoff, & Artis, 2013). Research into the microbiota
suggests people with diabetes have differences in both the diversity and the
distribution of organisms (Larsen et al., 2010; Qin et al., 2012a). Larsen and
colleagues (2010) describe differences in the distribution of common intestinal
bacteria phylum between persons with T2D and non-T2D persons. In this study,
researchers found diabetic subjects had a higher abundance of Bacteroidetes (M =
50.4% vs. M = 35.1%) and significantly fewer Firmicute bacterial groups
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(M=36.8% vs. M = 56.4%), such as Clostridia, compared to controls. Studies
comparing diversity suggest Firmicutes account for 60 to 70% of colonic bacterial
species and Bacteroidetes 28 to 30% (Yang, Xie, Li, & Wei, 2009; Wang, Ahrné,
Jeppsson, & Molin, 2005). Qin et al. (2012a) conducted a complex case-control
metagenome-wide association study among a Chinese cohort, reporting the
functional composition of bacteria differed between T2D and controls at the
genus level. In this study population, those with T2D were found to have fewer
butyrate-producing bacteria, which includes Clostridia species, and more
pathogenic bacteria when compared to non-diabetic controls. Of the 37 butyrateproducing bacteria identified from the sample, only 21% were present in the T2D
group, none of which were among previously isolated species of butyrateproducing bacteria located in the human colon (Qin et al., 2012b, p.30).
In a similarly designed study comparing European women, Karlsson et al. (2013)
identified differences in the composition and structure of fecal microbiota between
diabetics and non-diabetics. Karlsson and colleagues used their bioinformatics
methodology to compare their findings with the Chinese cohort data (Qin et al., 2012a),
observing similar differences in bacterial functional composition and metabolic pathways
existed between cohorts. However, differences in species diversity and abundance were
noted between the two cohorts perhaps reflecting differences between populations.
Differences in the distribution of select bacterial groups between those with diabetes and
non-diabetics could provide an opportunity for C. difficile to proliferate should favorable
conditions develop. Favorable conditions include disruptions to established intestinal
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bacteria, providing an opportunity for C. difficile bacteria to access nutrient sources not
otherwise available but necessary for replication and growth.
Sialic Acid
In the human intestine, sialic acids (Sias), perform several functional roles. Sias
are protein-bound monosaccharides characterized by a nine-carbon backbone and have an
essential role in the regulation of cellular function (Varki & Schauer, 2009). The most
abundant Sias in humans is N-acetylneuraminic acid (Varki & Schauer, 2009). Within
the mucous layer of the intestine, Sias provide a source of energy and nutrition for both
commensal and pathogenic bacteria (Vimr, Kalivoda, Deszo, & Steenbergen, 2004). Sias
also have a role in regulating host immune function (Varki & Gagneux, 2012).
Recent studies demonstrate that Sias are utilized by C. difficile as an energy
source. Ng and colleagues (2013) showed that C. difficile has the genetic ability to
catabolize mucosal mucin. Mucin, a glycoprotein found in intestinal mucous contain Sias
which bind to the terminal, non-reducing ends of oligosaccharide chains (Vimr et al.,
2004). However, for C. difficile to expand, the bacteria require an available source of
free sialic acid (Ng et al., 2013). This new understanding supports the hypothesis that
competition for nutrients and disruption to commensal bacteria provides an opportunity
for C. difficile to develop a niche in an otherwise limiting environment (Britton & Young,
2014).
Sialic Acid and Diabetes
Research into sialic acid (Sias) indicates people with diabetes have higher
amounts of circulating Sias compared to non-diabetics (Khalili et al., 2013; Schmidt et
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al., 1999: Varghese, Asha, Celine, & Prasanna, 2015). Schmidt and colleagues (1999)
identified an association between increased serum levels of Sias and orosomucoids, a
glycoprotein to which sialic acid binds, and incident diabetes among a large U. S. cohort.
A later study by Khalili et al. (2013) analyzing health data from a large Swedish cohort
also observed a positive relationship between serum Sias and increased risk for diabetes
and diabetic complications. Despite limitations for comparison due to differences in
population groups and the variables included in the analyses, both longitudinal studies
suggested that people with diabetes have elevated circulating concentrations of Sias.
Elevated levels of Sias in those with diabetes suggest a potential pathway by which
people with diabetes could become susceptible to CDI. For example, disruptions within
the microbiota, especially to commensal bacteria utilizing Sias as an energy source, could
increase availability for C. difficile bacteria and the potential for bacterial expansion
(Huang, Chassard, Hausmann, von Itzstein, & Hennet, 2015; Ng et al., 2013). The
association between Sias levels and diabetes are further supported by findings from
Varghese, Asha, Celine, and Prasanna (2015) who conducted a case-control study
evaluating the serum concentration of inflammatory markers, including Sias in patients
with T2D. Varghese and colleagues found participants with T2D had significantly higher
levels of serum Sias compared to non-diabetic controls.
Factors Associated with Disruptions to the Intestinal Microbiota
Antimicrobial therapy
A well-established relationship exists between exposure to antibiotic therapy and
an increased risk for CDI (Bartlett, Moon, Chang, Taylor & Onderdonk, 1978). The
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initial link between CDI and antibiotics was established by Bartlett, Moon, Chang, Taylor
and Onderdonk (1978) with the identification of C. difficile as a causative agent in
antibiotic-associated colitis. Over the past several decades’ researchers have shown most
classes of antibiotics related to an increased risk for CDI in hospitalized patients (Owens
et al., 2008). Variation in reported findings between classes of antibiotic reflects
differences in the susceptibility patterns and virulence among different strains of C.
difficile. For example, Vardakas, Konstantelias, Loizidis, Rafailidis, and Falagas (2012)
conducted a meta-analysis comparing risk characteristics for BI/NAP1/027 and nonBI/NAP1/027 C. difficile strains. Results from their analysis indicate different
susceptibility and resistance patterns exist between strains. BI/NAP1/027 strains were
associated with prior exposure to fluoroquinolones a class of antibiotics previously not
associated with an increased risk for CDI (Freeman & Wilcox, 1999). However,
Clindamycin, a predisposing factor in non-BI/NAP1/027, did not pose a significant
threat. These differences support increasing concerns regarding emerging antibiotic
resistance among select strains of CDI. Stevens, Dumyati, Fine, Fisher, & Van
Wijngaarden (2011) found evidence from a large prospective cohort study suggesting
cumulative exposure to antibiotics over time increases the risk for CDI, making links to
specific antibiotics challenging. The mechanism by which antibiotics predispose the host
to CDI results from the disruption to the host’s normal intestinal microbiota. This
disruption enables colonization and expansion of other microorganisms into previously
occupied niches. It is also suspected that antimicrobials are not the only medications to
have a disruptive effect on the microbiome.
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Proton pump inhibitors
Proton pump inhibitors (PPI) are a frequently utilized medication in hospitalized
patients and associated with an increased odd of developing CDI (Barletta & Sclar, 2014;
Buendgens et al., 2014; Dial, Alrasadi, Manoukian, Huang, & Menzies, 2004). Exposure
to PPI medications are thought to contribute to the risk for CDI by altering the diversity
of the intestinal microbiota (Bavishi, & DuPont, 2011; Imhann et al., 2015; Seto, Jeraldo,
Orenstein, Chia, & DiBaise, 2014). Although findings from several meta-analyses
(Arriola et al., 2015; Deshpande et al., 2015; Janarthanan, Ditah, Phil, Adler, &
Ehrinpreis, 2012) support an association between PPI exposure and CDI, the role of
gastric acid suppression in increasing susceptibility to CDI is not entirely understood.
Some researchers hypothesize that high gastric acidity destroys harmful pathogens
(Clooney et al., 2016; Janarthanan, Ditah, Phil, Adler, & Ehrinpreis, 2012; Jump, Pultz,
& Donskey, 2007). Suppression of gastric acid production then raises the gastric pH and
increases the bacterial load of pathogens within the gut environment. An early study by
Dial, Alrasadi, Manoukian, Huang, and Menzies (2004), found that patients receiving PPI
medication had an increased risk of CDI compared to those not exposed. Similar
findings from a case-control study were reported by the same research team (Dial et al.,
2004), investigating CDI risk while controlling for comorbidities and severity of disease.
More recently, both Barletta and Sclar (2014) and Buendgens et al. (2014) reported an
increased risk for CDI associated with PPI exposure among intensive care unit (ICU)
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patients. Links between PPI exposure and CDI onset are reported in several metaanalyses (Deshpande et al., 2015; Kwok et al., 2012; Tleyjeh et al., 2012). However,
substantial heterogeneity between these studies was noted as a limiting factor in the
analysis. Several studies found increased risk associated with PPI use and concurrent
antibiotic exposure when compared to PPI use alone (Gordon, Young, Reddy, Bergman,
& Young, 2016; Kwok et al., 2012). Recent evidence also suggests that long-term PPI
use may affect the microbiome. Clooney and colleagues (2016) reported different ratios
of Bacteroidetes and Firmicutes between PPI and non-PPI users. Such differences may
increase host susceptibility allowing C. difficile bacteria to grow and expand outside of
the stomach. This hypothesis is supported by findings from in vivo and cohort studies
(Imhann et al., 2015; Nerandzic, Pultz, & Donskey, 2009). Nevertheless, not all studies
have reported increased risk for CDI associated with PPI use. Novack and colleagues
(2014) found no statistically significant risk between PPI exposure and CDI when
comparing similar levels of disease severity, arguing that previously reported associations
are the result of differences between comparison groups. The findings by Novack et al.
(2014) mirror prior findings by Shah, Lewis, Leopold, Dunstan, & Woodhouse (2000)
who also found no association between risk for CDI and PPI use when comparing
samples testing positive for C. difficile toxin, and those that test toxin negative.
Furthermore, Faleck and colleagues (2016) examined the risks of PPI exposure in
patients in 14 ICU and found that PPI use did not to increase the risk for CDI nor was it
found to effect adverse outcomes following CDI infection.
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Although there is some discrepancy regarding exposure to PPI in hospitalized
patients, their use has relevance for the diabetic population experiencing gastrointestinal
complications of altered intestinal motility and gastroesophageal reflux disease. Such
complications may place diabetic patients at increased risk for CDI due frequent and
longer-term usage of gastric acid suppressing medications (Huang & Wang, 2009). The
frequent utilization of PPI among hospitalized patients, including those with diabetes is
important as PPI may confound the relationship between diabetes and CDI, similar to
antibiotic exposure.
Diabetic medications
Medications used in the management of diabetes, are thought to have some
impact on the microbiome. Metformin, an oral antihyperglycemic used in T2D, has been
found to reduce the risk of CDI in diabetic populations (Eliakim-Raz et al., 2014).
Eliakim-Raz and colleagues (2014) evaluated the risk of CDI among a sample of
hospitalized patients, using a case-control design. The researchers found patients on
metformin therapy were 42% less likely to develop CDI compared to patients on other
treatment modalities, such as insulin. The therapeutic effect of drugs, like metformin are
thought to come from metabolic alterations within the intestinal microbiome (Forslund et
al., 2015; Wu et al., 2017). Forslund et al. (2015) note that medication modalities
influencing the microbiome could have a confounding effect, and should be controlled
for in data analysis. The authors (Forslund et al., 2015) hypothesis was supported with
differences found in the intestinal microbiome of those taking metformin and those not
on metformin therapy. Specific differences included a decreased abundance of butyrate-

37
producing organisms in patients with T2D not on metformin, compared to those receiving
metformin. Butyrate-producing bacteria are thought to play a protective antimicrobial
role and depletion of these organisms is associated with an increased risk for CDI
(Antharam et al., 2013; Schubert et al., 2014). Studies examining cardiovascular risk in
T2D have also found patients taking metformin have lower levels of serum sialic acid
than those on alternative oral antiglycemics (Rahman, Malik, Bashir, Khan & Idrees,
2010).
Enteral feeding tubes
Patients receiving enteral nutrition via feeding tubes have been identified as
having an increased risk for CDI (Bliss et al., 1998; O’Keefe, 2010). In a study
specifically evaluating CDI in tube feed patients, Bliss et al. (1998) found patients
receiving tube feedings were nine times more likely to acquire CDI than non-tube feed
patients. Brown and colleagues (1990) also reported an association between nasogastric
(NG) tubes and increased risk for CDI in a case-control study. Although Brown, Talbot,
Axelrod, Provencher & Hoegg (1990), found patients with NG tubes to have 28 times
greater risk for CDI, the small sample size, and differences noted between case and
control patients makes these finding less reliable. For example, more than 25% of
controls came from the obstetrics and gynecology services which likely have healthier,
and younger female patients. Recent studies (van Werkhoven et al., 2015; Wijarnpreecha
et al., 2016) have continued to report an increased risk for CDI associated with the use of
gastric and nasogastric feeding tubes. However, smaller effect sizes are reported
compared to earlier studies (Brown, et al., 1990; Bliss et al., 1998). In contrast, Lin et al.
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(2015) conducted a prospective cohort study examining risk factors for CDI in a
Taiwanese population and found tube feeds were not a statistically significant risk factor
for developing CDI in both bivariate and multivariate analyses. Larentis, Rosa, De
Santos, and Goldani (2015) found no association between tube feeds and CDI in bivariate
analysis, but the authors did find tube feeding an independent risk factor associated with
poor outcomes in CDI.
Several mechanisms for the increased risk for CDI with the use of feeding tubes
have been proposed. These include the transfer of C. difficile bacteria by healthcare
workers during routine manipulation of the tubes (Best, 2008; Bliss et al.,1990; Brown et
al., 1990), and the potential contamination of enteral formula from the environment (Bliss
et al., 1998; Mutters et al., 2008). There are also some indications that the type of enteral
formula can alter the gut microbiota, promoting the expansion of bacteria, including C.
difficile in the gut (Iizuka et al., 2004). O’Keefe (2010) notes that elemental and lowresidual formulas, while readily absorbed in the small intestine lack the complex
carbohydrates and fiber that support a diverse and protective microbiota within the colon.
Disruptions to the microbiota from these types of formula can also provide an
opportunity for C. difficile to proliferate within the colon and cause disease (O’Keefe,
2010).
Prior healthcare location
The risk of CDI among the AR population could be affected by previous exposure
to healthcare settings, with patients exposed to risk factors, such as antibiotics and
contaminated environments. Information regarding the prevalence of CDI or
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colonization in the AR environment is limited. Marciniak and colleagues (2006)
investigated the prevalence of C. difficile colonization among rehabilitation patients
admitted from an acute care setting. Findings from this case-control study found 16% of
patients were colonized with C. difficile. However, evidence indicating prior
colonization as predictive of developing CDI was inconclusive. Other studies examining
the transmission of CDI among different hospital settings, reported higher estimated rates
of transmission among residents in long-term care (LTC) settings compared to the acute
hospital or the community (Durham, Olsen, Dubberke, Galvani & Townsend, 2016).
Ricciardi, Nelson, Griffith, and Concannon, (2012) also suggest that higher rates of CDI
among LTC residents result in an increase burden of CDI in acute care hospitals.
However, a recent study by Ziakas et al. (2016) among a national sample of LTC
residents, found that almost two-thirds of those diagnosed with CDI had a been
hospitalized within the previous 30 days or had a hospital discharge within the last 90
days. Similar findings were reported by Zarowitz, Allen, O’Shea, and Strauss (2015),
who evaluated a large national sample of nursing home residents. Results from this
research found only 21% of CDI cases were nursing-home acquired, and the majority,
85%, of cases were admissions from acute care hospitals. Although patients often move
between healthcare settings, most admissions to post-acute settings are from acute care
hospitals (Hunter et al.,2016; Zarowitz et al., 2015; Ziakas et al., 2016). In addition,
characteristics among cases, such as exposure to antimicrobials, underlying health
conditions, and older age are consistently identified across various healthcare settings
(Hunter et al.,2016; Zarowitz et al., 2015; Ziakas et al., 2016). Different healthcare

40
settings could impact the exposure burden of CDI. However, limitations noted in
previous research regarding an absence of data from prior hospitalizations, time from
exposure to infection, and sample size (Marciniak, Chen, Stein, & Semik, 2006; Mylotte,
Russell, Sackett, Vallone, & Antalek, 2013) reduces the value of adjusting for location in
the analysis.
Individual Host Factors
Age
Evidence of a correlation between advanced age and an increased risk of CDI
have been published both in the U.S. and globally. Lessa et al. (2015) reported
population estimates of incidence HAI-CDI in the U.S. among those 65 years of age and
older of 481.5 per 100,000 persons compared to only 83.1 per 100,000 persons aged 45 to
64 years. Similarly, an European population-based surveillance study of HAI- CDI found
persons over 65 years incurred three times the risk of CDI compared to those of younger
age (Bauer et al., 2011). Smaller studies have also reported older adults experience
higher risk for CDI and increased disease severity. Patel, Wieczorkiewicz, and Tuazon
(2016) found advanced age, defined as over 70 years, associated with a 2-fold increased
risk of developing severe CDI disease. Lee et al. (2016) also reported more severe illness
among hospitalized Korean patients 65 years and older compared to those under 65.
Using a prospective study design, Kurti et al. (2015) described CDI incidence in an
Eastern European hospital population. Although they reported 83% of CDI cases were
over 60 years of age, age alone was not a significant risk factor. Instead, an association
with disease severity and mortality was identified. The severity of illness among those
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with CDI is likely affected by multiple factors, including different bacterial strains.
Miller et al. (2010) found select C. difficile strain associated with worse outcomes.
Disease severity and C. difficile attributable mortality did increase with age, particularly
in those over 60 years. However, the very old experienced poor outcomes regardless of
C. difficile strain.
Race and ethnicity
Disease and health-related outcomes are frequently examined within the context
of race and ethnicity in the U.S. Understanding the role of race and ethnicity and social
determinants in health distribution is complex (Ichiro, Daniels, & Robinson, 2005).
Reports of racial and ethnic differences in CDI incidence and outcome measures suggest
that some level of health disparity may exist. Differences include higher rates of CDI in
White compared to non-Whites population groups. Lessa et al. (2015) analyzed
surveillance data from ten States across the U. S. and found rates for both incidence and
recurrent CDI higher in Whites compared to non-Whites. Also, Mao, Kelly, and Machan
(2015) and Olanipekun, Salemi, de Grubb, Gonzalez, and Zoorob (2016) examined the
effect of race on CDI. Using secondary data from the Healthcare Cost and Utilization
Project Nationwide Inpatient Sample (NIS), both studies reported higher rates of
infection among Whites compared to other racial and ethnic groups. Additionally, Mao
and colleagues found Whites more likely exposed to antibiotics than other races.
Findings from a study by Bakullari et al. (2014) suggest HAI occurs more frequently
among Asian and Hispanic populations. Asian populations also experienced a higher
occurrence rate of CDI, compared to White, non-Hispanic groups (0.5% vs. 1.1%) in a
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Medicare population. Murphy, Avery, Dubberke, & Huang (2012) also reported an
increased probability of healthcare-onset CDI among Asians compared to Whites.
However, non-Hispanic Whites were more likely to experience CDI following discharge.
Although not evaluated, such findings may reflect differences in access to care in the
outpatient setting (Murphy et al., 2012). In contrast to other studies, Freedberg et al.
(2013) found Black race associated with an increased risk for recurrent CDI when
evaluating PPI exposure. In this hospital-based cohort, the multivariate analysis found
Black race associated with increased risk for CDI compared to Whites. Differences in
CDI outcomes related to race and ethnicity indicate multiple factors and pathways
contribute to risk. Bakullari et al. (2014) suggested that language barriers could
adversely impact some population groups when hospitalized. Other variables such as
socioeconomic, environmental and social factors may also contribute increased risk for
CDI (Freedberg et al., 2013; Lessa et al., 2015). The increased risk for Caucasians found
in large inpatient population datasets, may reflect greater access and exposure to
healthcare settings and antibiotics compared to other minority groups.
Obesity
High BMI has been linked to both the risk of developing diabetes and CDI
(Bishara et al., 2013; Leung, et al., 2013; Leung, Carlsson, Colditz & Chang, 2016;
Nguyen, Nguyen, Lane, & Wang, 2011). The CDC (2016) classifies a normal or healthy
BMI between 18.5 and 24.9 and obese, as a BMI equal or greater than 30. Nguyen and
colleagues (2011), using data from the National Health and Nutrition Examination
Survey found 49% of diabetics were also obese based on their BMI. Ganz et al. (2014)
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conducted a case-control study using data from a large U.S. health system and found the
risk for T2D between 2.5 and 5 times greater among those within the obese BMI
categories. Leung, Carlsson, Colditz, and Chang (2016) also reported a strong
association between obesity and risk for diabetes using population-based health
utilization data. There is also evidence suggesting a link between obesity and the risk of
developing CDI. Bishara et al. (2013) conducted a case-control study testing the
hypothesis that obese persons may have increased susceptibility to CDI compared to lean
persons, based on potential differences in the gut microtia between the groups. Findings
from their multiple regression analysis found obesity an independent risk factor in CDI
among this study population. Leung and colleagues (2013) also investigated the
relationship between obesity and the risk for CDI among hospitalized patients. Results
from their retrospective analysis suggest an association between obesity and CDI, among
those without prior exposure to healthcare facilities after controlling for antibiotic use.
No significant relationship was found between obesity and healthcare-associated CDI.
However, the small sample size suggests the study may not have had adequate power to
detect a statistically significant association.
Disease severity
A potential confounder in the relationship between diabetes and CDI is the
severity of diabetes. Diabetes can adversely affect the body’s vascular systems (Fowler,
2011). The resulting damage to the macro and microvascular systems contribute to
complications such as cardiovascular disease, peripheral vascular disease, stroke,
nephropathy and retinopathy (Fowler, 2011). Complications of diabetes are also
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associated with increased morbidity and mortality (Steiner & Friedman, 2013). Steiner
and Friedman (2013) examined comorbidities among hospitalized patients using data
from the NIS. The analysis found diabetes was a frequent discharge comorbidity among
those with three or fewer underlying conditions across all age groups. Of interest, the
proportion of adults with four or more chronic diseases was highest for Whites, while
Hispanics had the least. The number of presenting complications and risk for CDI could
reflect the overall health status of patients, measured as the number or the type of health
complications on admission. Wenisch et al., (2012) investigated risk factors for severe
CDI in a small sample of hospitalized patients, noting more than 60% of the sample had
moderate to severe underlying diseases based on the Charlson commodity index.
Multivariate analysis found only diabetes, chronic kidney disease and chronic pulmonary
disease associated with increased risk of severe CDI, and diabetes associated with higher
odds of infection. The authors reported no association between disease severity and
increased age. A limiting factor in the interpretation of these results is the potential for
inadequate power due to the small sample size, especially when correlations between
increasing age and disease severity have been identified (Kyne, Sougioultzis, McFarland,
& Kelly, 2002; Murphy et al., 2012). Murphy et al. (2012) identified individual
characteristics predictive for CDI included age and diabetes in both bivariate and
multivariate analysis. Tartof and colleagues (2014) also reported higher proportions of
CDI cases among those with diabetes and severe diabetes in addition to 14 additional
underlying conditions.
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Most studies examining CDI address the potential confounding of underlying
conditions on the outcome. However, few studies differentiate between the diabetes
severity as was done in the study by Tartof et al. (2014). Interestingly, there is evidence
suggesting that diabetes may be protective against CDI. Stewart and Hollenbeak (2011)
analyzed NIS data from 2007, evaluating risk factors associated with excess attributable
costs and mortality between those with and without CDI. In their analysis, both diabetes
and diabetes with complications resulted in lower odds of dying compared to those
without CDI. This unexpected finding may reflect less virulent strains circulating in
hospitals during the sampling period or less precise testing methods than currently
available. In addition, the use of administrative databases poses limitations related to the
availability of clinical data such as diagnostic results and medications specific to
individual patients.
Clostridium difficile Infection and Diabetes
Few studies have examined the association between diabetes and CDI despite the
increasing prevalence of both diseases. A recently published population-based study
examining CDI among patients with T2D reported an overall prevalence of CDI among
hospitalized patients with T2D of 6.8 per 1000 acute care discharges (Olanipekun et al.,
2016). Thus, people with diabetes could account for a large number of cases when
compared to national estimates of 13.8 CDI cases per 1000 discharges (Jarvis, Schlosser,
Jarvis, & Chinn, 2009). Olanipekun et al. also reported a positive correlation between
CDI and increased mortality, duration of hospitalization, and cost. Although Olanipekun
et al. reported on findings from a large randomized cohort of hospitalized patients, the
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sample excludes post-acute patients in rehabilitation and long-term acute care hospitals.
However, with an estimated 76% of hospitalized patients discharged to post-acute
settings (Burke et al., 2015), the prevalence of CDI in the diabetic population was likely
underestimated. Shakov, Salazar, Kaqunye, Buddora, & DeBan (2011), found people
with diabetes had an increased for recurrent CDI. Since the outcome of interest was
recurrent disease, no association between incident CDI risk and diabetes was evaluated.
Limited evidence suggests diabetic patients who develop CDI may have unique
characteristics. For example, Hassan, Rahman, Huda, Wan Bebakar and Lee (2013)
found diabetic patients with CDI were younger and diagnosed with sepsis, thus more
likely to have received antibiotics. However, the validity of their results is limited by the
small number of CDI cases included in the analysis. More recently, Olanipekun et al.
(2016) analyzed data from a large U. S. national sample, and found differences in race
and income when comparing those with diabetes and CDI and diabetics without a
diagnosis of CDI. Similar to other reported studies (Mao, Kelly, and Machan, 2015), the
Olanipekun et al. (2016) study found a higher proportion of CDI occurring in Whites.
Differences associated with income were also noted, with a larger proportion of those
with CDI having higher household incomes while lower income was positively related to
an increased length of stay, associated costs, and risk for mortality. The differences
noted by Olanipekun et al. may reflect the impact socioeconomic status and overall health
status have on those with diabetes.
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Summary and Conclusions
Investigations into the relationship between diabetes and CDI have been
observational and most often using historical data. The inability to infer causation is an
inherent weakness of observational studies (Rothman, Greenland, Poole, & Lash, 2008),
as even well-designed observational studies remain vulnerable to unexpected or unknown
confounding variables. Within the reviewed literature, differences in sample populations
and sample size were frequent, and likely explained the variation in reported outcomes.
For example, sample sizes ranged from 159 patients in a single hospital setting (Hassan et
al., 2014) to over 3,000,000 patients included in a national inpatient database over a tenyear period (Olanipekun et al., 2016). Differences in geographical locations and
healthcare settings also existed, although the majority of studies included hospitalized
patients from acute care settings. Some researchers used large population-based samples
to examine CDI outcomes providing a nationally representative population from which to
interpret and extrapolate findings. Population-based samples drawn from national data
sources often provide access to large samples which strengthen the credibility of the
results. However, such samples have limitations. For example, the NIS database
contains data from a large number of participating community hospitals yet, excludes
data from post-acute hospital settings such as rehabilitation and long-term care facilities
(Healthcare Cost and Utilization Project [HCUP], 2016). Other limitations of
administrative databases are the accuracy and availability of data extracted from medical
records. Differences between studies also existed regarding the measurement of
variables, in particular, comorbidities. The most frequently used measure of disease
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severity identified in the literature was the Charlson Comorbidity Index, although
variation in the presentation of included variables was noted. Other strengths identified
from this review include consistencies in the diagnosis of CDI, with studies using similar
testing processes and definitions.
Conclusion
This review of the literature addressed several major themes related to diabetes
and CDI. The role of the intestinal microbiota is shown to have a strong influence in
regulating the immune system, as well as limit available niches for pathogenic bacteria.
The development of commensal flora and balanced ecosystem within the intestinal
environment depends on the availability of essential nutrients and the organism’s ability
to access and utilize them. Research into the role of Sias as a nutrient source for C.
difficile bacteria and as an indicator of inflammatory processes in persons with diabetes
raises the question as to whether diabetes poses an increased risk for CDI. Few studies
have specifically examined the relationship between diabetes and CDI. Most research
into CDI outcomes include diabetes as a comorbidity measure related to disease severity,
rather than a primary risk factor. Exposure to antibiotics adversely affects the risk for
CDI through organism resistance and disruption to the commensal bacteria of the gut.
Such disturbances, in turn, support the opportunistic expansion of C. difficile bacteria.
Exposure to PPI medications may also contribute to CDI, although the mechanisms for
this association are not well understood. Host characteristics such as age, race,
underlying disease states and disease severity also appear to contribute to CDI. Despite
the myriad of research related to CDI, understanding the determinants contributing to
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disease onset remains unclear. In addition, little research appears to focus on the impact
of CDI among hospitalized patients with diabetes. This literature review has identified
possible mechanisms unique to diabetic patients contributing to an increased risk for CDI
in this population.
My study evaluating the relationship between diabetes and CDI addresses the
need for data regarding CDI in the diabetic population. This study also fills a gap in the
literature regarding CDI risk factors in the post-acute setting. Addressing the deficits
identified in the literature is an important step for CDI prevention. The following chapter
discusses the design and methodology elements of this study, including a description of
the population, sampling, and analysis strategies
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Chapter 3: Research Method
Introduction
A case-control research design was used to answer the research questions
regarding the relationship between diabetes and CDI, and the presence of modifiable risk
factors among diabetic patients. The main purpose of this study was to assess the
association between diabetes and CDI among the acute-rehabilitation population.
Evaluation of this relationship included controlling for select environmental and host
characteristics. For this study, the outcome variable was the presence of CDI and the
independent variable diabetes. Control variables include age, ethnicity/race, gender,
admission diagnosis, health status, functional independence, and diabetes disease
severity. The second aim of this study was the identification of environmental and host
characteristics sensitive to modification in the diabetic population. Other independent
variables of interest include antibiotic use, gastric acid suppressants, diabetic
management, BMI, and the presence of gastric feeding tubes.
Chapter three presents the proposed methodology to answer the aforementioned
research questions. This chapter describes the research design and supporting rationale.
Variables included in the analysis are presented and operationalized. This chapter also
describes the sampling plan, the data collection methods, the ethical considerations
pertinent to this research study, and a discussion regarding potential threats to the
external and internal validity of the proposed study. Finally, the methods for the
statistical analysis and testing of hypotheses are described.
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Research Design and Rationale
Independent and dependent variables of interest are diabetes and CDI,
respectively. Variables acting as potential confounders include antibiotics, obesity and
PPI. Persons with diabetes may experience greater exposure to antibiotics, thereby
increasing their risk for CDI. Likewise, diabetics may also have increased exposure to
PPI medications resulting from disease-related complications, and there is evidence
suggesting PPI may increase the risk of CDI. Potential confounders include patient
comorbidities which could influence the strength of the relationship between the
independent and dependent variable, including obesity. Age is a potential confounding
variable associated with both increased risk of diabetes and CDI. Covariates include
ethnicity/race, gender, admission diagnosis, duration of hospital stay, diabetes disease
severity, obesity, and underlying co-morbidities.
Case-control designs support the evaluation of exposure-disease associations and
allows for retrospective comparison of factors which may contribute to the risk of disease
(Szklo & Nieto, 2014). The comparison between cases and controls can generate
estimates of exposure prevalence and risk factors in the source population (Rothman,
Greenland & Lash, 2008, p.112). Case-control studies support the use of secondary data
and for use in diverse and dynamic populations such as those found in hospital settings
(Carlson & Morrison, 2009; Vandenbroucke & Pearce, 2012). A defining characteristic
of case-control studies is the selection of cases based on the outcome of interest, which
for this study is CDI. The case-control design is also useful when studying infrequent or
rare outcome events. Although CDI is an HAI of concern, the estimated incidence of

52
CDI among the acute care settings is less than 20% (Magill et al., 2014) with an
estimated frequency of 15 % among the AR population (Mylotte, Graham, Kahler,
Young, & Goodnough, 2000).
Methodology
Population
A total of 7953 discharge records were identified for the study period, August 01,
2009, and September 30, 2015, with 217 records having an ICD-9 code for CDI. The
final number of cases meeting the inclusion criteria was 102. Both cases and controls
came from the same source population. The source population included all patients
discharged from a New Mexico free-standing urban AR hospital during the defined study
period. This acute inpatient rehabilitation hospital accepts patients from throughout the
State with an estimated 1200 discharges per year. The average length of stay at this
hospital is 14 days. Patients access the AR setting to improve their functional
independence while still receiving inpatient hospital care, allowing patients to return to
their homes and communities.
Sampling and Sampling Procedures
Participant selection
The following plan outlines the strategies used to increase the representativeness
of the participants in this study and reduce sampling errors. For this study, all available
cases, and a sample of eligible controls was drawn from the same target population. A
positive laboratory test for C. difficile toxin during an episode of hospitalization was
needed to meet the criterion as a case. Randomly selected patients discharged during the
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study time frame without a positive test for C. difficile toxin were eligible for inclusion in
the control group. The exclusion criterion for both cases and controls were discharged
patients under the age of 18, and those patients receiving treatment for CDI at the time of
admission as noted in the admission history and physical.
The target population consisted of all discharged patients from the research site
during specified study period. The following procedures describe the selection of both
cases and control samples. A query of the facility administrative data was used to
generate a list of all patients discharged during the study period. Information requested
for this query was limited to discharge date, ICD-9 code discharge diagnoses, and
medical record number. ICD-9 code 089.45 provided the initial screen to identify cases
of CDI. The medical record number was necessary to locate the correct medical record
for review in the absence of an electronic medical record. Use of ICD-9 codes to query
nosocomial CDI has been used previously with good sensitivity, but limited specificity
when compared to laboratory results (Scheurer, Hicks, Cook, & Schnipper, 2007). To
limit the potential for misclassification, laboratory results were reviewed to confirm the
CDI diagnosis. All verified CDI cases meeting the inclusion criteria were included in the
case group. For each case, two controls were selected from the list of discharged
patients. The discharge list was organized by date and controls selected using the
medical record number located above and below the case subject. In the event,
consecutive cases were identified, the next available units above and below the cases
were selected, maintaining the 1:2 ratio. This method of control selection reduced
potential sampling bias by increasing the likelihood that controls were from the same
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population that produced the cases.
A priori power analysis
This research study used a fixed sample capturing all eligible CDI cases identified
during the study period. An estimated 25 cases of hospital-associated CDI were reported
at the facility each year. This estimate was based on historical infection control
surveillance reports. Prior to data collection, a priori analysis of the expected power was
conducted. Information from the power analysis provided an estimation of type 2 error
associated with a sample of this size. OpenEpi software (Dean, Sullivan, & Soe, 2002)
was used to generate the power analysis for a two-tailed test with the estimated sample
size of 125cases during the originally proposed 57-month study period of January 1, 2011
through September 30, 2015. The level of significance was set at 5%, with a 95%
confidence interval. An odds ratio of 2 was estimated from the proportion of diabetes
exposure among cases and controls obtained from previously reported data (Weeks,
2009, Meng, Pickett, Babey, Davis, & Goldstein, 2014). Review of the literature
suggested the estimated proportion of hospitalized patients with diabetes ranges from
18% in the rehabilitation setting (Weeks, 2009), to almost 20% in the acute care settings
(Fraze, Jiang, & Burgess, 2010), although estimates of 30% have also been reported
(Meng et al., 2014). Additional selected studies reported that 24 to 38 % of CDI cases
also had a history of diabetes (Abdelsattar et al., 2015; Hunter et al., 2016; Tartof et al.,
2014; Zilberberg et al., 2014). Based on this reported data, the percent of exposure
among cases was estimated at 30%. The power analysis calculation indicated that the
estimated sample size is unlikely to achieve the desired 80% power (Table 1).
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Table 1
Results of A priori Power Analysis
Input Options

Input Data

Two-sided confidence interval (%)

95

Number of cases

125

Percent of exposure among cases (%)

30

Number of controls

250

Percent of exposure among controls (%)

18

Odds Ratio

2

Power: Normal approximation

74.28%

Note. Power analysis generated for unmatched case-control study using OpenEpi statistical software
(Dean, Sullivan, & Soe, 2002). Number of cases is estimated from an estimated number of CDI cases
occurring each year at facility.

Data Collection Methodology
The initial data collection study period from January 1, 2011, through September
2015 found 140 records coded for CDI. However, 71 did not meet the inclusion criteria.
Exclusion criteria included receiving treatment for CDI at time of admission (n = 40), or
laboratory test results negative for C. difficile toxin. Twenty-four records coded for CDI
were negative for toxin, although positive for antigen, and seven records were miscoded
with either negative results reported or no documented test result. The number of actual
cases (n = 69) was unable to provide adequate power, increasing the risk of a Type II
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error. Thus, the study period was extended to include an additional 24 months, following
approval from the Walden University IRB. The second set of data found a total of 77
potential cases. Unfortunately, access to discharged records was restricted to patients
discharged after August 1, 2009, resulting in the removal of 31 cases and 50 controls. Of
the remaining available CDI coded records (n = 46), one was excluded due as unable to
locate scanned chart, and 11 were excluded due to CDI treatment at the time of
admission.

Figure 2. Flowchart
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Data Extraction Procedures
The analysis dataset for this case-control study was constructed utilizing a
secondary data source. Permissions to build a data set from information documented in
the hospital medical record was granted by the Chief Executive Officer at the study site.
The permission process included review of the dissertation proposal by the facility’s
leadership and risk management department. In addition to permissions obtained from
the healthcare facility, Walden University Institutional Review Board (IRB) approval was
obtained prior to commencing data collection.
Once the study participants were selected, the medical record for each subject was
reviewed for study eligibility. The medical record provided documentation regarding the
medical history, and clinical care of patients, by trained healthcare providers. A manual
chart review of each eligible record was conducted, and data for each study variable
extracted and recorded on a standardized data collection form. A new data collection
form was completed for each subject and identified using a unique study code.
Demographic variables collected included age, sex, ethnicity, and length of stay. Care
was taken to extract only that data necessary to answer the research questions and
avoided the collection of any patient identifying information. Use of a data collection
tool supports a standardized approach to data abstraction and increases the internal
validity and reproducibility of the study (Gregory & Radovinsky, 2012). Data from the
collection tool was inputted into an Excel spreadsheet (www.microsoft.com), creating the
data set for statistical analysis. A manual process for review and data extraction was
necessary as the research site used a paper-based medical record.
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Instrumentation and Operationalization of Constructs
Instrumentation
Patient co-morbidities and disease complications in this sample were measured
using the modified Cumulative Illness Rating Scale (CIRS). The CIRS as a measure of
comorbidity has been used previously in rehabilitation related research, including
orthopedic, stroke and burn patient populations (Bejor, Ramella, Toffola, Comelli, &
Chiappedi, 2013; Giaquinto et al., 2001). It combines two indexes, a cumulative index
and a severity index (Linn, Linn & Gurel, 1968; Salvi et al., 2008). Researchers have
also found the CIRS a valid and reliable tool for research use (de Groot, Beckerman,
Lankhorst, & Bouter, 2003). The CIRS rates 13 items organized by body system, and
uses a 5-point severity rating, ranging from no impairment (0) to extremely severe
impairment (4). Summing of all items provides an overall impairment measure.
Limitations with this scale include the element of clinical judgment in assigning severity
scores. However, having defined parameters can improve the reliability of severity
scoring.
The severity of diabetes disease was measured using the Diabetes Complications
Severity Index (DCSI) (Young et al., 2008). This 13-point complication index provides a
measure of risk for adverse diabetes outcomes using the type and number of
complications present (Young et al., 2008). Complications included in the DCSI are
cardiovascular disease, metabolic, nephropathy, neuropathy, peripheral vascular disease,
retinopathy, and stroke. The DCSI was developed using laboratory data and ICD-9
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codes, with each complication group categorized into three levels (no abnormality = 0,
some abnormality = 1, severe abnormality = 2) depending on the presence and severity of
the complication. The DCSI was developed and validated using 4229 participants
enrolled in a larger longitudinal prospective population-based cohort in the U. S. (Young
et al., 2008). The DCSI was selected for this study as it specifically measures the
severity of complications in a diabetic population and addresses a broad range of
complications associated with the disease.
A third instrument used to evaluate the functional independence of patients
admitted to AR was the Functional Independence Measure (FIM). In the U.S., the FIM
provides both a measure of disability at admission and the functional gains following
inpatient medical rehabilitation. Developed in the 1980’s, the FIM is a product of the
American Academy of Physical Medicine and Rehabilitation and the American Congress
of Rehabilitation Medicine. The FIM software is available and licensed through Uniform
Data System (UDS) for Medical Rehabilitation (www.udsmr.org). The extensive use of
the FIM in the U.S. is in part due to the quality reporting requirements for inpatient
rehabilitation facilities receiving reimbursement through CMS (Granger, 2013).
Documentation of the admission and discharge FIM is recorded in the medical record for
later extraction and upload to the UDS database.
The FIM instrument consists of 18 items; thirteen items measure motor tasks and
five items address cognition (Rehabilitation Institute of Chicago [RIC], 2013). The
patient’s level of independence is evaluated by certified clinicians. The measure of
independence is, based on an individual’s ability to complete defined tasks. Tasks are
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rated on a 7-point ordinal scale, where 1 is complete dependence requiring total
assistance and 7 is complete independence. The level of function is calculated from the
total score which ranges from a minimum score of 18 to maximum score of 126 (RIC,
2013). The FIM assessment is conducted at admission and repeated at discharge.
The FIM has been shown to have high internal consistency and validity across a
range of rehabilitation diagnoses, with strong construct validity (RIC, 2013). Dodds and
Colleagues (1998) evaluated internal consistency for a general rehabilitation population,
reporting an admission FIM using Cronbach’s α of .93, and a discharge FIM of α = .95.
More recent evaluation of relatability and validity of the FIM in rehabilitation burn
patients reported overall Cronbach’s α of .96 for motor scales and .97 for cognitive
scales, and strong construct validity scalability coefficients > 0.5 (Gerrard et al., 2013).
Although studies indicate strong internal consistency, variability in routine use among
personal, and the potential for missing data may reduce the internal validity.
Operationalization of Variables
The following table (Table 2) describes each of the variables, the level of
measurement, and how each variable is operationalized.
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Table 2
Operationalization of Study Variables
Variable

Type of

Operational Definition

Values

Positive assay or PCR for C.
difficile toxin laboratory
results

1 = Yes

Documentation of diabetes
in the admission H & P

1 = Yes

Variable
CDI

Diabetes

DV

IV

0 = No

0 = No

Admission
diagnosis

IV

Rehabilitation admission
diagnosis group as defined
by CMS

1 = stroke, 2 = spinal cord injury, 3
= multiple trauma, 4 = brain injury,
5 = amputation, 6 = burns, 7 =
lower limb fractures, 8 = complex
orthopedic conditions, 9 =
musculoskeletal, 10 = neurological
disorders, 11 = debilitation

Age

IV

Age of participant at the
time of admission.

Minimum value =19

Sex

IV

Documented sex

1 = Female
2 = Male

Ethnicity

IV

Documented ethnicity

1 = Caucasian
2 = Hispanic
3 = Black/African American
4 = Asian
5 = Native Hawaiian or Other
Pacific Islander
6= American Indian,
7 =Other
Blank = unknown; Missing

Antibiotics

Height

IV

IV

Documentation of
antibiotics received by
participants in prior 30 days
before discharge

1 = Yes

Documented height on
admission (Used to
calculate BMI variable)

Continuous variable in inches

0 = No
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Variable

Type of

Operational Definition

Values

Variable
Weight

IV

Documented weight at time
of admission (Used to
calculate BMI variable)

Continuous variable in pounds

BMI

IV

Body mass index, calculated
from documented height
(inches) and weight
(pounds)

1 = Underweight = <18.5
2 = Normal weight = 18.5–24.9
3 = Overweight = 25–29.9

Other disease states
documented in the
admission record

Nominal

Comorbidities assessed by
body system to Provides a
measure of whole person
impairment based on the
sum of 13 system items

Score range from 0 to 52

Comorbidities

Cumulative
Illness Rating
Scale (CIRS)

IV

IV

4 = Obesity = BMI of 30 or greater

Diabetes
Complication
Severity Index
score (DCSI)

IV

Evaluates presence and
severity of diabetes related
complications: Retinopathy,
Nephropathy, Neuropathy,
Cerebrovascular,
Cardiovascular, Peripheral
vascular disease, Metabolic

Score range 0 to 13

Diabetes Control

IV

Prescribed method of
controlling blood glucose
levels

1 = diet
2 = oral
3 = insulin
4 = both insulin and oral

Tube feeding

IV

Presence of a feeding tube

0 = No
1 = Yes

FIM

IV

Functional Independence
Measure assessed on
admission

Scored18 to 126

PPI

IV

Documentation of Proton
pump inhibitor drug
administered in prior 30
days before discharge

0 = No

Note. DV = dependent variable; IV = independent variable

1 = Yes
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Data Analysis Plan
IBM SPSS Statistics [Version 23.] software was used to conduct all analysis of
the data. The data was cleaned and frequencies examined to identify outliers. For
variables with outlying values, the associated data collection form was reviewed for
errors in data entry and corrected. Distribution of continuous variables was examined for
assumptions of a normal distribution. Data cleaning techniques to limit the effect of
potential errors included replacing outlying values with the next highest score that is not
an outlier (Field, 2013). This method avoided deletion of data from the analysis and
thereby reduction of the sample size. One record was removed from the dataset due to
the substantial number of variables with missing data.
Research Questions
Research Question 1: Is there any relationship between diabetes and CDI among
hospitalized patients in the acute rehabilitation (AR) setting?
Research Question 2: Are modifiable environmental (antimicrobial and
medication exposures) and host characteristics (behaviors, BMI, diabetes management)
associated with CDI among hospitalized diabetics in the AR setting?
Statistical Tests and Procedures
Descriptive statistics were measured and examined to describe characteristics of
the sample. The distribution of continuous variables was assessed using measures of
central tendency and dispersion including the mean and standard deviation. Categorical
data was presented as proportions. Differences between groups were tested using the
independent t-test. Had data not followed a normal distribution, non-parametric tests
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such as the Mann-Whitney U or Wilcoxon Rank Sum test would have been employed.
Categorical variables were analyzed using Person’s Chi-square (χ2) to measure the
association between two groups.
Exploratory analysis of the data included evaluating variable frequencies,
assessment of interactions between the exposure variable and covariates, and assessment
of potential confounders. Continuous independent variables were assessed for linearity
and multicollinearity. In response to the small fixed sample size, independent variables
were transformed into dichotomous variables. This decision was made following review
of the cross-tabulated frequencies to ensure the assumption of expected frequencies was
not violated with all cells having a minimum frequency of five. Assessment of effect
modifiers and confounders was based on analysis of the literature presented in chapter 2.
Research Question 1
To test the relationship between diabetes and CDI Pearson's chi-square test was
conducted. To adjust for potential confounding variables, hierarchical multiple logistic
regression modeling was used to test the study hypotheses. Hierarchical backward
elimination was used (Kleinbaum & Klein, 2010) to determine the best estimate of the
relationship. The initial model (Table 5) included all potential confounding variables and
the effect modifying term to create a baseline model for comparison from which to assess
which variables could be eliminated from the final model. To determine the best fitting
model variables were excluded in turn from the model and model refitted. Initial models
included all covariates. Only those risk factors found significant (p ≤ 0.05) or deemed
relevant based on previous research were retained in the final models. Results of both
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bivariate and multivariate regression models are reported as odds ratios. Changes to the
exposure variable, diabetes, were assessed for change in odds ratio and precision as noted
by 95% confidence interval. Null hypothesis testing was set at the 5% probability level
(p-value ≤ 0.05), two-tailed. Estimates of population parameters had a 5% margin of
error, and are reported as 95% confidence intervals.
Research Question 2
Multivariate logistic regression was used to examine the second research
question. The total sample was split to include only those with diabetes in the regression
analysis. Variables excluded from the analysis include age, sex and ethnicity as these are
non-modifiable host characteristics. Also eliminated were exposures such as having a
feeding tube, having had gastric surgery. The health-status variable FIM score was also
excluded, as deficits in functional status are justification for admission to an AR facility.
Variables retained for inclusion were antibiotic, and PPI exposure, BMI as a potential
indicator of nutritional status, CIRS as this instrument included host behaviors related to
alcohol, substance and tobacco abuse in scoring criteria. Variables specific to the
diabetic population, diabetic severity index and diabetic medications were included as
these are reflective of disease management and monitoring.
Backward hierarchal logistic regression was conducted assess for potential
confounders. Because no primary exposure was identified, and evidence of potential
confounding present, all variables were inputted into the final model for analysis. Null
hypothesis testing was also set at the 5% probability level (p-value ≤ 0.05), two-tailed
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and estimates of population parameters had a 5% margin of error, and reported as 95%
confidence intervals.
Threats to Validity
External Threats
Potential threats to validity included both external and internal sources (FrankfortNachmias & Nachmias, 2008). External sources of bias include unknown differences
between cases and the controls. Such differences can limit the generalizability of
findings to other population groups beyond the study sample. Unrecognized threats
impacting external validity can lead to incorrect conclusions and inferences from the
sample data to different population groups, settings, or temporal situations (Creswell,
2008). For this study, potential threats limiting the generalizability of the results include
selection bias due to the type and location of the healthcare facility, and the study period
(Creswell, 2008; Burns & Grove, 2005). Efforts to minimize these potential threats
included avoiding inferences beyond those groups included in the sample and within the
specific healthcare setting. For example, extending claims beyond the AR hospital
setting. Also, endemic strains of C. difficile or the emergence of new strains may limit
generalizations to other geographic regions or time frames.
Internal Threats
Internal validity describes the exclusion of rival explanations for the identified
association between variables (Frankfort-Nachmias & Nachmias, 2008). Factors that
pose a threat to the internal validity of this study come from errors introduced during the
study design, conduct, or analysis process (Rothman, Greenland, & Lash, 2008). Specific
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internal validity threats include uncontrollable differences between the cases and controls
during the sample selection process. Measures used to reduce this risk included drawing
the control group from the same population as cases during the same time frame. Other
threats include historical events occurring during the study period (Frankfort-Nachmias &
Nachmias, 2008) such as changes in C. difficile testing methods, or testing
recommendations, which can impact the effect of the relationship between variables.
Additionally, the presence of confounding variables can distort the association between
diabetes, the independent variable, on the outcome of interest. Unknown or extraneous
variables not captured in the analysis dataset could have a confounding effect, leading to
over or underestimation of the effect size (Rothman, Greenland & Lash, 2008).
Information bias is another internal validity threat resulting from the misclassification of
exposure or diagnosis (Rothman, Greenland, and Lash, 2008; Szklo & Nieto, 2014). The
use of secondary data can increase this threat due to unknown errors in documentation,
administrative coding, or missing information.
Additional threats to validity include drawing inaccurate conclusions about the
data (Creswell, 2009). Threats associated with statistical validity include inadequate
sample size, where the available sample size, does not provide adequate power to detect
an effect, increasing the risk of a type 2 error (Ellis, 2010). Calculating the study power a
priori can mitigate this risk by adjusting other associated parameters such as increasing
the sample size or the effect size. Imprecise variable definitions and measures can also
pose a validity threat (Creswell, 2008). Careful consideration and documentation of
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variables, including variable definitions, scales of measurement, and appropriate selection
of statistical tests reduce the risk of erroneous conclusions.
Ethical Procedures
Protecting the anonymity and confidentiality of personal health information was
of paramount concern in this case-control study. Ethical considerations specific to this
research study included the type of personal health information collected and the
safeguarding of sensitive health information during the data collection process. These
concerns included determining how best to protect the privacy and dignity of discharged
patients (Frankfort-Nachmias-Nachmias, 2008; Santelli, 2013). Formal approval to
conduct this research study was granted by the Walden University IRB (Approval
number 04-25-17-0379668). The IRB application included a signed Data Use Agreement
from the research site authorizing the collection and analysis of their data.
This study utilized archival data located in the hospital medical record. Risk of
patient harm associated with the collection of data for this study was minimal. This risk
assessment was based on the retrospective nature of the study, with data originally
collected during routine patient care. No intervention or contact with patients or clinical
personal was required for data collection. In addition, no patient identifying information,
such as patient name, date of birth, social security number, medical record number, or
residence data was included in the final dataset. Regardless of the risk, protecting the
privacy rights and respect for the patient were recognized, and measures aimed at
preserving the anonymity and confidentiality of the individual’s health information
implemented (Frankfort-Nachmias & Nachmias, 2008). Methods employed to protect the
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privacy of patient information located within the medical record included exclusion from
the dataset any data that could potentially identify patients and the collection of deidentified data only. De-identification includes the removal of any personal and
geographical information possibly resulting in disclosure of the patient’s identity and
includes administrative data such as hospital episode numbers. Other measures to protect
patients included reducing the risk of data linking by separating the initial list of
discharged patients which contained hospital episode numbers and the final dataset.
Limiting the collection of information to only that necessary to answer the research
question and aggregating the data for analysis also increased adherence to the ethical use
of health information.
Professional and ethical conduct across all aspects of the research process is
essential to protect the privacy of patients and the organizations in which research is
conducted. Ethical behavior is a direct concern when research is done in one’s
professional workplace. Conducting research in such settings can introduce issues related
to bias, perceived coercion, and breaches of confidentiality. Measures to limit these risks
in this study included the use of a secondary data source, and maintaining a clear
separation of clinical/professional and investigator roles. Separation of roles included
collecting data outside of scheduled work hours. To avoid potential and actual breaches
of confidentiality, all chart review was conducted in a private area and limited to only
those sections of the record relevant to the variables of interest.
Protecting confidential data and maintaining its integrity requires measures to
securely manage and store the collected data both electronically and in hard copy. The
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dataset is stored electronically on a password-protected portable hard drive. A single
backup copy of the dataset is stored in a locked cabinet. Both the hard drive and backup
storage devices will be maintained for at least five years as required by Walden
University. The dataset does not contain identifying information. Each study record was
assigned a unique identifier code. Once the dataset was completed, the master list which
included hospital encounter numbers was destroyed. The use of a master list containing
the encounter number was necessary to generate the list of discharged patients and to
locate the medical charts of the sample for manual review. This master list was critical as
the research site did not have an electronic medical record, instead, the facility used a
paper documentation system. Following patient discharge, the medical record is
electronically scanned for archival storage. During active data collection, the master list
provided the only linkage to the dataset, with access limited to the researcher.
Summary
A case-control study design was selected to evaluate an association between
diabetes and CDI among AR patients. In this study, the dependent variable is CDI and
the independent variable, diabetes. The data analysis plan was based on a fixed number
of available cases, with two controls identified for each case. Although the selection of
cases was drawn from all available CDI discharges during the study period, the controls
were randomly selected from non-CDI discharges within the same time-period. The
medical record of discharged patients meeting the inclusion criteria provided the
secondary data for the study. Data collection activities included a review of the medical
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record and subsequent extraction of select information necessary to measure the
variables, and construction of a de-identified dataset.
The use of a case-control design poses a risk for selection and information bias.
Both forms of bias can threaten the internal validity of the study. Efforts to minimize
selection bias included the random sampling of controls, and selecting controls from the
same population that produced the CDI cases. Use of a standardized data collection tool
and a documented process for addressing missing data also helped control for information
bias. Another potential risk to validity is the effect of confounding variables. Use of
multivariate logistic regression allowed for controlling of covariates within the analysis,
as a means of addressing the threat of confounding variables.
This third chapter describes the data analysis plan used to answer each one of the
research questions and test the study hypothesis. This plan included a description of the
study sample and the statistics used to compare cases and controls. Bivariate and
multivariate logistic regression models were used to evaluate the relationship between
diabetes and CDI and to identify modifiable risk factors. Charts, tables, and narrative are
used to summarize the results of this study.
Ethical considerations are a critical element of any research study. For this
dissertation research, permission was granted by Walden University IRB. In addition,
authorization to access the medical records of discharged patients at the proposed
research site was given by the facility CEO. Measures to protect the privacy of patient
information included the purposeful extraction of data to exclude any patient identifying
data, the secure storage of the dataset, and the aggregate analysis of data.
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Chapter 4: Results
Introduction
The purpose of this research study was to evaluate the association between
diabetes and CDI. Specifically, to assess if there is a relationship between diabetes and
CDI among hospitalized patients in the acute rehabilitation (AR) setting and if are there
any modifiable environmental and host characteristics associated with CDI among
hospitalized diabetics in this select setting. This chapter describes the sample population,
and present results of the multiple logistic regression analysis used to answer the
aforementioned research questions.
Results
Sample Characteristics
Participants age ranged from 21 to 97 years with a negatively skewed distribution
(Figure 3.). BMI values fell between 13.7 to 59.9, with positive skew and leptokurtic
distribution (Figure 4.). Both CIRS and FIM showed normal distribution. Among those
with diabetes, the DCSI score ranged from 0 with no complications to a score of 13;
distribution had a positive skew and negative kurtosis. The majority of those with
diabetes managed their disease with insulin (16%) or a combination of oral and insulin
therapies (13%).
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Figure 3. Age distribution and frequency of age
by years.

Figure 4. Distribution and frequency of sample
BMI.

The sample available for analysis was predominately female (51.8%) with a mean
age of 68 years (Table 3). Across both cases and controls, most participants were
Caucasian (59.4%), Hispanic/ Latino (28.3%), Native Americans (9.5%).
Black/African Americans (1.9%) and Asian (0.8%) were in the minority. The most
frequent diagnosis among patients admitted to the AR facility was orthopedic conditions
(28.3%), followed by stroke and debilitation, with each accounting for 17% of the
sample. Those categorized as other (10.6%) included patients admitted with arthritis,
cardiac or pain syndrome diagnoses. Among those with CDI, debilitation was the most
frequent diagnosis (29.1%), while for controls, orthopedic conditions (30.5%) the most
common.
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Table 3
Characteristics of Sample Population by Outcome Variable
Characteristics

Age, years, mean (SD)

Total
Sample
(N = 473)
68.17 (14.21)

Cases
(n = 102)

Controls
(n = 371)

68.06 (13.94)

68.20 (14.30)

Sex (%)

p-value (95% CI)

.931 (-2.99, 3.26)
.219

Female

245 (51.8)

47 (46.1)

198 (53.4)

Male

228 (48.2)

55 (53.9)

173 (46.6)

Race/ Ethnicity (%)

.756

Caucasian

281 (59.4)

66 (64.7)

215 (58.0)

Hispanic

134 (28.3)

27 (26.5)

107 (28.8)

African American

9 (1.9)

1(1.0)

8 (2.2)

Asian

4 (.8)

AI/AN

45 (9.5)

8 (7.8)

37 (10.0)

BMI, mean (SD)

27.20 (6.75)

26.32 (5.84)

27.45 (6.97)

.136(-.36, 2.61)

Diabetes, yes (%)

176 (37.2)

46 (44.7)

131 (35.3)

.107

4 (1.1)

Admit Diagnosis (%)

.001*

Stroke

81 (17.1)

11 (10.8)

70 (18.9)

Spinal Cord

31 (6.6)

6 (5.9)

25 (6.7)

Multiple Trauma

6 (1.3)

2 (2.0)

4 (1.1)

Brain Dysfunction

38 (8.0)

6 (5.9)

32 (8.6)

Amputation

28 (5.9)

11(10.8)

17 (4.6)

Burns

1 (.2)

LE Fracture

1 (.2)

1 (1.0)

Orthopedic Cond.

134 (28.3)

20 (19.6)

114 (30.7)

Neurological

22 (4.7)

3 (2.9)

19 (5.1)

Debilitation

81 (17.1)

30 (29.4)

51 (13.7)

Other

50 (10.6)

12 (11.8)

38 (10.2)

1 (.3)

Prior Location (%)

<.001*

Acute Care

426 (90.1)

Home

7 (1.5)

Long-term Acute

33 (7.0)

16 (15.7)

17 (4.6)

Nursing Home

7 (1.5)

4 (3.9)

3 (.8)

17.97 (5.32)

19.83 (4.81)

17.46 (5.35)

CIRS, mean (SD)ǂ

82 (80.4)

344 (92.7)
7 (1.9)

<.001* (-3.47, -1.30)
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Characteristics

Cases
(n = 102)

Controls
(n = 371)

DCSI, mean (SD) †

Total
Sample
(N = 473)
3.64 (3.17)

3.84 (3.12)

3.57 (3.19)

.621 (-.136, .811)

FIM, mean (SD)

82.61 (21.84)

76.73 (21.47)

84.23 (21.69)

.002* (2.75, 12.26)

Antibiotics, yes (%)

315 (66.6)

84 (82.4)

231(62.3)

<.001*

PPI, yes (%)

205 (43.3)

60 (58.8)

145 (39.1)

<.001*

Tube Feeding, yes (%)

39 (8.2)

15 (14.7)

24 (6.5)

.013*

GI Surgery, yes (%)

11 (2.3)

7(6.9)

4 (1.1)

.003*

Diabetes Therapy (%)

†

p-value (95% CI)

.047*

Diet

18 (10.3)

4 (8.9)

14 (10.8)

Insulin

78(44.6)

27 (60.0)

51 (39.2)

Oral

62 (35.4)

9 (20.0)

53 (40.8)

Oral & Insulin

17 (9.7)

5 (11.1)

12 (9.2)

Note. *Statistically significant at p-value ≤ 0.05, two-tail; CI = confidence interval
† Variable includes only those with a diagnosis of diabetes at time of admission to AR facility.
ǂ Levene’s Test for Equality of variance significant (p-value < 0.05) values reported do not assume equal
variance.

Differences between groups were tested using the independent t-test for
continuous variables and Fisher’s exact test for categorical variables. Ninety percent (pvalue < 0.001) of patients transferred from acute care settings, and seven percent from
long-term acute care facilities (LTAC). Comparisons between acute care and other
healthcare settings for CDI frequency, found statistically significant differences between
both LTAC (X2 (1) = 15.59, p = <0.001) and nursing home settings (X2 (1) = 6.21, p =
0.03) as prior locations. Notable differences (p-value ≤ 0.05) were also found among
variables related to exposure and health status. Comparison of means between cases and
controls found differences between CIRS and FIM scores with CDI cases having a higher
average CIRS score (m = 19.83) compared to those who were not diagnosed with CDI (m
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= 17.46). Patients with CDI (n = 102) were found to have lower mean FIM scores (m =
76.73) indicating less functional independence, compared to the control group (m =
84.23). Fisher’s exact test was used to evaluate differences in categorical variables
between cases and controls, with differences (p-value <0.05) noted for prior exposure to
antibiotics, protein pump inhibitors (PPI), the presence of a feeding tube, GI surgery
within 30 days of admission, admission diagnosis, and prior location. Similar
frequencies between the two groups were found among host characteristics of age,
gender, and ethnicity. No statistically significant differences were also noted among the
health status variables body mass index (BMI), and diagnosis of diabetes.
For continuous variables, all interactions tested were found non-significant (pvalue > 0.05) indicating that the assumption for linearity was met. Assessment of
collinearity found tolerance values less than 0.1 and variance inflation factor (VIF) less
than 10, suggesting no violation of this assumption. An interaction between age and
diabetes, with differences in effect size, was found to exist between those aged 65 and
younger and those older than 65 years (Table 4).

Table 4
Observation of Age as an Effect Modifier
≤ 65 Yrs.

>65 Yrs.

Variable

OR

p-value

95% CI

OR

p-value

95% CI

Diabetes

2.20

.032

1.07, 4.52

1.12

.708

.631, 1.97

Note. Statistically significant at p value ≤ 0.05, two-tail; CI = confidence interval
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Research Question 1 and Hypothesis
Research Question: Is there any relationship between diabetes and CDI among
hospitalized patients in the acute rehabilitation (AR) setting?
Ho1: There is no relationship between diabetes disease and CDI among patients in
the AR setting.
H11: There is a significant relationship between diabetes and CDI among patients
in the AR setting.
Thirty-six percent of the sample was admitted to the AR hospital with a diagnosis
of diabetes. Results of the Pearson's chi-square test found no association (X2 (1) = 2.66, p
= 0.10) between diabetes and CDI. The crude odds ratio (OR = 1.45), as a measure of
effect, suggested those with diabetes were 45% more likely to develop CDI than nondiabetics. However, this finding was not statistically significant (p = 0.10; 95% CI [0.93,
2.26]). Evaluation for the presence of effect modifiers influencing the relationship
between diabetes and covariates found age to modify the relationship between diabetes
and CDI, evidenced by increasing both the odds ratio and the statistical significance of
the association (table 4).
To determine the effect of potential confounding on the relationship multivariate
logistic regression modeling was conducted. Variables selected for inclusion were those
identified from bivariate logistic regression to have a statistically significant (p-value ≤
0.05) association with CDI, and those considered relevant risk factors were included: age,
gender, ethnicity, BM, CIRS, FIM, admission diagnosis group, prior location, antibiotics,
PPI, feeding tube, GI surgery, and age x diabetes interaction (Table 5).
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Table 5
Full Logistic Regression Model Containing All Potential Confounding and Interaction
Variables
95% CI
Variable

B

SE

Wald

df

p-value

OR

Lower

Upper

Diabetes

1.075

.473

6.047

1

.014*

2.930

1.244

6.902

Age >65

.409

.348

1.380

1

.240

1.505

.761

2.976

Male

.776

2.53

1.189

1

.275

1.318

.802

1.166

Caucasian

.452

.266

2.878

1

.090

1.571

.932

2.648

BMI >25

-.571

.257

4.034

1

.045*

.596

.360

.988

CIRS

.018

.029

.37 1

1

.542

1.018

.962

1.077

FIM

-.015

.006

5.543

1

.019*

.986

.974

.998

Admit Group: Debility

.383

.330

1.348

1

.246

1.467

.768

2.802

Acute Care Loc:

.858

.398

4.645

1

.031*

2.358

1.081

5.143

Antibiotic

.987

.306

10.44
4

1

.001*

2.684

1.475

4.886

PPI

.416

.255

2.655

1

.103

1.515

.919

2.498

Feeding Tube

.273

.425

.413

1

.521

1.314

.571

.3024

GI Surgery

1.664

.687

5.869

1

.015*

5.280

1.374

20.293

AGE*Diabetes

-.930

.521

3.191

1

.174

.394

.142

1.095

Constant

-1.739

.849

4.196

1

.041

.176

Note. Statistically significant t at p-value ≤ 0.05, two-tail; CI = confidence interval

A hierarchical backward elimination modelling assessment found the variables
gender and having a feeding tube to have negligible effect as potential confounders and
were removed from the final model. Although, the CIRS variable had the least
significance, having this variable in the model provided a narrower confidence interval
and was retained in the final model (Table 6). In the final model, having had GI surgery
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in the 30 days before admission was excluded due to the imprecise confidence interval,
95% CI [1.37, 20.29], likely resulting from the small number of patients.

Table 6
Final Hierarchical Multiple Logistic Regression Model Controlling for Confounding and
Interaction Variables

B
.929

SE
.428

Wald
4.703

df
1

p-value
.030*

Age: >65

.327

.340

.924

1

.366

1.387

.712

2.700

Caucasian

.389

.261

2.214

1

.137

1.475

.884

2.461

-.494

.252

3.841

1

.050*

.610

.373

1.000

.031

.028

1.268

1

.260

1.032

.977

1.090

-.015

.006

6.570

1

.010*

.985

.973

.996

Acute Care Loc.

.799

.383

4.351

1

.037*

2.223

1.049

4.709

Admit Group: Debility

.420

.322

1.696

1

.193

1.522

.809

2.863

1.046

.299

12.207

1

<.001*

2.846

1.583

5.116

.493

.250

3.879

1

.049*

1.637

1.002

2.672

MD*Age

-.855

.513

2.776

1

.096

.425

.155

1.163

Constant

-2.099

.832

6.369

1

.012

.123

BMI: ≥ 25
CIRC
FIM

Antibiotic
PPI

Exp(B)
2.531

95% CI
Lower Upper
1.093 5.858

Variable
Diabetes

Note. Nagelkerke R Square =.181. * statistical significance p-value ≤ 0.05, two-tail; CI = confidence
interval

After controlling for potential confounders, the sample of acute rehabilitation
patients with diabetes had 2.53 greater odds of developing CDI compared to those
without diabetes (p = 0.03, 95% CI [1.09, 5.86]). Including the variable GI surgery in the
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past 30 days prior to admission increased the odds ratio but reduced estimate precision
(OR = 2.8, Wald = 5.689, p = 0.017, 95% CI [1.20, 6.61]). Based on these findings, the
null hypothesis that there is no association between diabetes and CDI was rejected in
favor of the alternate hypothesis that there is an association between diabetes and CDI
after controlling for race, BMI, CIRC, FIM, coming from an acute care location, debility
admitting diagnosis group, and exposure to antibiotic and PPI medications.
Research Question 2 and Hypothesis
Research Question 2: Are modifiable environmental (antimicrobial and
medication exposures) and host characteristics (behaviors, BMI, diabetes management)
associated with CDI among hospitalized diabetics in AR settings?
Ho2: There is no relationship between selected modifiable variables and CDI
among diabetic patients in the AR setting.
H12: There is a relationship between modifiable variables and CDI among
diabetic patients in the AR setting.
Descriptive statistics to explore differences between those with diabetes and nondiabetics are presented in Table 7. Several statistically significant differences were noted
with a higher percentage of Native Americans (15.9% vs. 5.7%, p = 0.003) having a
diagnosis of diabetes. Differences were also noted amongst Hispanics who also had a
higher proportion of diabetes (34.1% vs. 24.9%, p = 0.032) and Caucasians who had
higher numbers of non-diabetics (67.7% vs. 45.5%, p < 0.001). No differences were
found for African Americans or Asian ethnicities. Differences between groups were also
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found for BMI, admission diagnosis, CIRS. No differences were found between groups
for antibiotic or PPI exposure, FIM score, prior location, feeding up or GI surgery.

Table 7
Characteristics of Sample by Exploratory Independent Variable
Characteristics

Age, years, mean (SD)
Sex (%)

Total
Sample
(N = 473)
68.17 (14.21)

Diabetes
(n =176)

No Diabetes
(n = 297)

68.35 (12.33)

68.06(15.24)

ǂ

.833 (-2.94, 2.37)
.634

Female

245 (51.8)

94 (53.4)

151 (50.8)

Male

228 (48.2)

82 (46.6)

146 (49.2)

Race Ethnicity (%)

< .001*

Caucasian

281 (59.4)

80 (45.5)

201 (67.7)

Hispanic

134 (28.3)

60 (4.1)

74 (24.9)

Black/AA

9 (1.9)

5 (2.8)

4 (1.3)

Asian

4 (.8)

3 (1.7)

1 (0.3)

AI/AN

45 (9.5)

28 (15.9)

17 (5.7)

BMI, mean (SD)

27.20 (6.75)

29.40 (7.4)

25.92 (5.9)

CDI, yes (%)ǂ

176 (37.2)

45 (25.6)

57 (19.2)

Admit Diagnosis (%)

<.001 (-4.71, -2.24) *
.107
< .001*

Stroke

81 (17.1)

27 (15.3)

54 (18.2)

Spinal Cord

31 (6.6)

9 (5.1)

22 (7.4)

Multiple Trauma

6 (1.3)

3 (1.7)

3 (1.0)

Brain Dysfunction

38 (8.0)

16 (9.1)

22 (7.4)

Amputation

28 (5.9)

20 (11.4)

8 (2.7)

Burns

1 (.2)

1 (0.3)

LE Fracture

1 (.2)

1 (0.3)

Orthopedic Cond.

134 (28.3)

32 (18.2)

102 (34.3)

Neurological

22 (4.7)

8 (4.5)

14 (4.7)

Debilitation

81 (17.1)

40 (22.7)

41(13.8)

Other

50 (10.6)

21 (11.9)

29 (9.8)

Prior Location (%)

p-value (95% CI)

.201
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Characteristics

Acute Care

Total
Sample
(N = 473)
426 (90.1)

Home

7 (1.5)

Long-term Acute

33 (7.0)

14 (8.0)

19 (6.4)

Nursing Home

7 (1.5)

3 (1.5)

4 (1.13)

17.97 (5.32)

20.03 (4.87)

16.74 (5.20)

CIRS, mean (SD)ǂ
DCSI, mean (SD) †

No Diabetes
(n = 297)

159 (90.3)

267 (89.9)

p-value (95% CI)

7 (2.4)

<.001 (-4.21, -2.34) *

3.64 (3.17)

FIM, mean (SD)
Antibiotics, yes (%)

Diabetes
(n =176)

ǂ

PPI, yes (%)ǂ
Tube Feeding, yes (%)
GI Surgery, yes (%)

ǂ

ǂ

82.61 (21.84)

82.65 (21.30)

82.59 (22.19)

.977 (-4.15, 4.03)

315 (66.6)

126 (71.6)

189 (36.4)

.087

205 (43.3)

80 (45.5)

125 (42.1)

.502

39 (8.2)

10 (5.7)

29 (9.8)

.166

11 (2.3)

4 (2.3)

7 (2.4)

1.00

Diabetes Therapy (%)†
Diet

18 (10.3)

Insulin

78(44.6)

Oral

62 (35.4)

Oral & Insulin

17 (9.7)

Note: *Statistical significant at p-value ≤ 0.05, two-tail; CI = confidence interval
† Variable includes only those with a diagnosis of diabetes at time of admission to AR facility.
ǂ Fishers Exact test

The final model (Table 8), indicate those with diabetes, when exposed to
antibiotics have 4.2 times greater odds of acquiring CDI compared to those who did not
receive antimicrobial therapy (OR = 4.24, p = 0.005). For patients receiving insulin the
odds of diabetes were 2.6 (p = 0.015). Exposure to PPI medication increased the odds of
CDI compared to diabetic patients who did not receive PPI. CIRS appeared to have a
confounding effect on PPI exposure (Table 9). Overweight and obese persons had a
lower risk of CDI compared to normal and underweight with each unit decrease in BMI
the odds of CDI were reduced by 0.43. However, neither the relationship between PPI
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and CDI or between BMI and CDI were statistically significant. Diabetes severity,
measured using the Diabetes Complication Index Score was also not a significant risk
factor, although less severe disease did lower the odds of CDI. However, a wide
confidence interval was noted across all these variables. The analysis found antibiotic
exposure (OR = 3.86, p = 0.010) and insulin therapy (OR = 2.56, p = 0.015) as modifiable
risk factors for CDI. Therefore, the null hypothesis that there are no modifying factors in
this population was rejected in favor of the alternate hypothesis that modifying factors are
present among diabetic AR patients after controlling for BMI, DCIS, CIRS, and PPI.

Table 8
Multiple Logistic Regression Examining Modifiable Risk Factor Among Diabetics
95% CI
Risk Factor

B

SE

Wald

df

p-value

Exp(B)

Lower

Upper

Antibiotic

1.352

.527

6.579

1

.010*

3.867

1.376

10.869

PPI

.612

.400

2.338

1

.126

1.844

.842

4.041

BMI ≥ 25

-.561

.405

1.922

1

.166

.570

.258

1.262

CIRS

.037

.045

.678

1

.410

1.038

.950

1.135

Insulin

.941

.385

5.961

1

.015*

2.563

1.204

5.456

DCIS

-.041

.066

.376

1

.540

.960

.843

1.093

Constant

--3.079

1.046

8.655

1

.003

.046

Note. Hosmer and Lemeshow Test: X2 (8) = 7.524 (p-value = 0.481); Nagelkerke R square =
.174; * statistically significant at p-value ≤ 0.05, two-tail; CI = confidence interval.
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Table 9
Observed Effect of CIRC on Logistic Regression Model Examining Modifiable Risk
Factor Among Diabetics
Adjusted Model with CIRS

Adjusted Model without CIRS

95% CI

95%CI

Risk Factors

OR

p-value

Lower

Upper

OR

p-value

Lower

Upper

Antibiotics

3.867

.010

1.376

10.869

3.748

.012

1.342

10.469

PPI

1.844

.126

.842

4.041

2.076

.051

.997

4.325

.570

.166

.258

1.262

.553

.141

.251

1.218

Insulin

2.563

.015

1.204

5.456

.382

.012

.180

.830

DCSI

.960

.540

.843

1.093

.382

.730

.867

1.105

CIRS

1.038

.410

.950

1.135

3.748

.012

.046

.003

.234

.036

BMI >25

Constant

Note. Adjusted model without CIRS: Hosmer and Lemeshow Test: X2 (8) = 3.83 (p = 0.871); Nagelkerke R
square = .169; * statistically significant at p-value ≤ 0.05, two-tail; CI = confidence interval.

Summary
The purpose of this study was to examine the relationship between diabetes and
CDI and to identify any modifiable risk factors associated with CDI in the acute inpatient
rehabilitation setting. This chapter presented the results of the data analysis conducted to
address the two research questions related to above-noted purpose. Of the initial 7593
records identified during the study period, a total of 473 records met the inclusion criteria
for analysis. Comparisons between cases and controls found differences related to
admission diagnosis with cases having a higher frequency of amputation and debility, and
having come from a post-acute setting. The control group had a higher frequency of
antibiotic exposure. Among those with a diagnosis of diabetics, a higher percentage of
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cases were prescribed insulin to manage their disease compared to oral or combination
regimes. Hierarchical multivariate logistic regression conducted to evaluate the
relationship between diabetes and CDI, suggested that diabetes is associated with CDI
after controlling for potential confounding variables in this population. Age was
identified as an effect modifier in the relationship. Results from this analysis should be
interpreted with caution due to the small number of cases, the small effect size, and
presence of interacting variables.
Findings from the analysis examining modifiable risk factors among this acute
rehabilitation population with diabetes found only exposure to antibiotics and insulin to
have an association with CDI of statistical significance. Interpretation of these findings,
including both significant and non-significant results, implications for positive social
change, and future recommendations will be discussed in Chapter 5.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Clostridium difficile is a leading cause of healthcare associated infection in the
United States (Magill et al., 2014) and is associated with a significant health and
economic burden (Desai et al., 2016; McGlone et al., 2012). Diabetes is a highly
prevalent disease associated with increased healthcare utilization from disease-related
complications (Zhuo et al., 2014). The purpose of this research was to evaluate the
association between diabetes and the risk for CDI and to identify any modifiable risk
factors specific to patients with diabetes. The study used an ecosocial theory of disease
distribution as the theoretical framework. The knowledge gained from this research will
increase the understanding of CDI in select healthcare populations and settings.
Our case-control study examined the relationship between diabetes and CDI
among patients discharged from an acute medical rehabilitation facility. Multiple logistic
regression was used to test for the association between the dependent variable CDI and
the exposure variable, diabetes. Results indicated a statistically significant association
between diabetes and increased odds for CDI. The study also sought to identify the
presence of modifiable risk factors for CDI among diabetic patients in this healthcare
setting. The results found antibiotic exposure and insulin therapy associated with an
increased odds ratio for CDI in this population sample.
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Interpretation of Findings
Research Question 1
Results of the analysis testing the association between diabetes and CDI found
patients with diabetes had increased odds of developing CDI after controlling for
confounding variables. Identifying an association between diabetes and CDI in this
sample population supports previous research examining alterations and differences in
the intestinal flora of persons with diabetes (Karlsson et al., 2013; Larsen et al., 2010;
Qin et al, 2012a). Such differences are permissive with intestinal microbiota diversity
shown among population groups attributed to variation in diet, genetic characteristics,
exposures and disease states (Escobar et al., 2014). Admissions to healthcare settings,
altered nutritional status, and medications have also been cited as impacting the intestinal
biome (Buonomo & Petri, 2016). These factors and cumulative exposures among
persons with diabetes may explain the increased odds for CDI and support previous
studies suggesting susceptibility to CDI is increased among those with diabetes (Shakov
et al., 2011; Tartof et al., 2014; Wenisch et al, 2012).
Exposure to antibiotic therapy in the previous 30 days at time of admission had
the strongest relationship for with CDI (OR 2.8, p = <0.001, 95% CI [1.6, 5.1]). A result
concurring with findings reported in the literature suggesting disruption to the intestinal
microbiota leads to expansion of C. difficile bacteria (Becattini, Taur, & Pamer, 2016;
Theriot et al., 2014). In my study, differences in the frequency of antibiotic exposure
were noted in the diabetic population. Antibiotic exposures were more common among
those with CDI. However, when comparing persons with diabetes to non-diabetics
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(Table 7) no difference in exposure was found. Frequently of exposure to antibiotics may
be related to disease states. Patients admitted to the AR setting from acute care facilities
may have greater exposure to antibiotic therapy based on their state of health, medical
intervention, and standard antibiotic utilization. Admission to the AR hospital setting
from acute care and LTAC locations was found to increase the odds of CDI in this
sample. This differs from opposite findings in the acute care literature where admission
from long-term care or nursing homes is considered a risk factor (Durham et al., 2016).
Possible explanations for the discrepancy in my study may indicate that a prior exposure
to any healthcare setting, acute or long-term, may increase the risk for CDI, or that the
duration of exposure to other healthcare settings, including the facilities underlying
burden of CDI increases the risk of infection.
Antibiotic exposure could be related to the admission diagnosis, with a greater
proportion of non-diabetic patients admitted following orthopedic surgery in which a
single prophylactic dose of antibiotics is routinely given as part of surgical site
prevention (Berríos-Torres et al., 2017; Bratzler et al., 2013). Also, patients with
diabetes may have experienced longer duration or cumulative exposure to antibiotics with
debilitation, the most frequent reason for admission.
Study participants older than 65 years of age were found to have an increased risk
for CDI, however this finding was not statistically significant. Although, age did not
have a confounding effect on the relationship between diabetes and CDI, the variable was
an effect modifier of this relationship. Previous studies have found higher incidence of
CDI among those of older age (Lessa, 2015; Pechal, Lin, Allen, & Reveles,2016). Non-
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significant findings in this study may reflect the differences in patients admitted to the
AR setting compared to acute care facilities or other geographical locations.
Research Question 2
The second research question examined modifiable risk factors associated with
CDI among diabetics only. In this sub-sample of patients with diabetes, recent exposure
to antibiotics (within prior 30 days) and glucose control medication (insulin therapy)
were found associated with an increased risk for CDI. Exposure to antibiotics increased
the odds of CDI by more than three-fold. Although there was no significant difference in
the frequency of antibiotic exposure between diabetics and non-diabetics in this study,
studies examining antibiotic utilization indicate that those with diabetes are more likely to
receive broad spectrum antibiotics (Jenkins et al., 2014; Jääskeläinen, Hagberg, Forsblom
& Järvinen, 2017) and for a longer duration of time (Jääskeläinen et al., 2017). More
aggressive treatment of infection and prophylaxis use in surgical patients is likely based
on previous studies linking diabetes disease to an increased risk of infection and infection
related mortality (Martin et al., 2016; Magliano et al., 2015). However, such prescribing
practices can lead to unnecessary exposure to antibiotics and increased risk for CDI
(Stevens, 2011). Thus, efforts to reduce exposure including antibiotic selection, and
minimal duration of therapy have strong potential in CDI prevention activities.
Among those on medications for glucose control, insulin therapy was associated
with an increased risk for CDI. Recent studies have also found insulin to increase the
risk of infection in hospitalized patients with diabetes, while oral antiglycemics have
been found to lower the risk for CDI (Eliakim-Raz et al., 2014). The protective quality of
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oral antiglycemics, has been linked to increased microbial diversity within the gut. Oral
antiglycemics increase butyrate-producing organisms (Antharam et al., 2013; Zhang et
al., 2017), which in turn is thought to limit available energy sources for C. difficile
expansion. However, the overall role of oral therapies and insulin is likely confounded
by factors such as therapeutic dosing, combination therapies, and the role of long-acting
insulins and glucose control. It is worth considering the impact of increased monitoring
and tighter control of blood glucose levels in hospitalized patients. In addition, insulin is
recommended over other antihyperglycemic agents in hospitalized patients for blood
glucose management (ADA, 2016), which may account for the higher insulin utilization.
The CIRS index includes elements of diabetes control within the score allocation, using
hemoglobin A1c results. The CIRS index provided a measure of comorbidity and
included measures of behavior such as tobacco, alcohol, or other dependent behaviors.
CIRS index was found to be significantly higher when compared to non-diabetic patients.
However, this variable was not found to offer significant value to the model. Early
evaluation of patients for resuming home regimes or appropriateness of
antihyperglycemic agent could reduce insulin exposure and limit risk for CDI.
Limitations of the Study
This study is subject to several limitations including the use of a case-control
design. Inherent limitations within the case-control design increase the potential for bias.
Informational bias could result from differences in the quality of information within the
medical record and misdiagnosis. Efforts to mitigate this risk included the use of a
standardized collection tool and confirmatory review of test results for inclusion as a
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case. Laboratory conformation of C. difficile toxin did eliminate a sizeable proportion of
cases (53%) originally identified using the ICD-10 codes. It is also possible that not all
cases of CDI occurred during the AR admission. Marjolein and colleagues (2012)
reported the highest risk for CDI occurring within the 30 days following antibiotic
exposure. Thus, cases of CDI occurring after discharge from the AR hospital but within
the 30-day window were not captured for analysis.
Adherence to the inclusion criteria also impacted the final sample size available
for analysis and the ability to generate adequate power to confidently accept observed
differences between groups. There was also the possibility of underrepresentation of
cases if patients experienced onset of symptoms post discharge. This study focused on a
specific healthcare population. Therefore, findings from this study may not transfer to
other healthcare settings. In addition, characteristics of the sample may reflect unique
characteristics of the geographical location and patient population within the U. S.,
particularly characteristics related to age and ethnicity. The inability to control for all
possible risk factors also limits the interpretation of the findings. Although, patient
comorbidities were measured and included as covariates, the use of index scores
prevented further drill down into specific behaviors or conditions, and a consideration for
future studies
Recommendations
Recommendations for future research include expanding study populations to
other geographical locations and healthcare settings. Using a broader population offers
the potential to obtain larger samples and to compare findings between different
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healthcare settings. Other recommendations based on the methodology of the current
study and theoretical framework is the further exploration of the multiple pathways
related to both susceptibility and resistance to CDI among patients with diabetes.
Pathways related to social economic status and environmental exposures, as well as a
more detailed approach in controlling for comorbidities and health-related behaviors.
Implications for Positive Social Change
There are several implications for positive social change because this study
focuses on a topic important for local and national efforts in HAI prevention. The high
morbidity and mortality associated with healthcare-associated CDI have led to prevention
efforts becoming a public health priority at the national level (Centers for Disease
Control and Prevention, 2013; Office of Disease Prevention and Health Promotion,
2016). Findings from this research have the potential to identify select population groups
at risk CDI, and more importantly to identify modifiable risk factors for CDI.
Understanding associations between at-risk populations, such as those with diabetes, and
CDI expand what is currently known about this infection and may offer insights and
opportunities for clinicians and researchers to develop targeted prevention strategies and
interventions. Findings from this research have the potential improve health outcomes
among those with diabetes in the post-acute healthcare settings by improving the quality
and safety of healthcare delivery. Insights from this research could also impact health
outcomes of diabetics by improving the quality and safety of healthcare delivery, through
reinforcing the role of antibiotic stewardship programs and appropriate prescribing
practices by clinicians in post-acute settings. Addressing the burden of CDI through
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effective prevention efforts also has economic implications for reducing healthcare costs,
both direct and indirect for the individual and healthcare facilities. In addition,
improving health outcomes among those with diabetes disease also offers economic
benefits for all levels of society.
Conclusion
Healthcare associated infections place a considerable burden on individuals,
healthcare systems and society as a whole. HAI reduction is increasingly becoming a
measure of quality care and linked to national healthcare policy. CDI has been identified
as a leading cause of HAI and associated with increased morbidity and mortality. Efforts
to understand the mechanisms contributing to CDI suggest disruptions to the intestinal
microbiome have a key role. Increasingly research on the intestinal microbiome indicates
a number of pathways or exposures over time create unique ecosystems. Differences
have also been found among those with diabetes when compared to non-diabetics. Yet
little research has been conducted to address CDI in the diabetic population. There is
also limited research regarding CDI in the AR setting.
To my knowledge, this is the first study to examine the relationship between
diabetes and CDI in the AR hospital setting. Findings from this study showed that those
with diabetes in an AR hospital were more likely to develop CDI compared to nondiabetics. Risk factors sensitive to intervention were found for antibiotic and insulin
exposure. The role of antibiotics as a risk factor reinforces the need for judicious use of
antibiotics across the healthcare spectrum. The role of insulin as a risk factor remains
unclear; however increased awareness among clinicians of the potential risk supports a
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proactive approach to diabetes management in the AR setting. Additional research is
needed to further our understanding of the relationship between diabetes and CDI and the
factors which increase CDI susceptibility and resilience. This study advances what is
currently known regarding the relationship between diabetes and CDI and moves us
closer to improving healthcare outcomes.
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